diff --git a/manuscript.html b/manuscript.html
index 77cd37be2..6b7690a20 100644
--- a/manuscript.html
+++ b/manuscript.html
@@ -58,7 +58,7 @@
   <meta name="author" content="Jeremy P. Kamil" />
   <meta name="author" content="Jesse G. Meyer" />
   <meta name="author" content="Ariel I. Mundo" />
-  <meta name="dcterms.date" content="2023-01-20" />
+  <meta name="dcterms.date" content="2023-01-24" />
   <meta name="keywords" content="covid-19, coronavirus, pandemic, viral infection" />
   <title>SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics</title>
   <style>
@@ -104,11 +104,11 @@
   <meta name="citation_title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
   <meta property="og:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
   <meta property="twitter:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
-  <meta name="dc.date" content="2023-01-20" />
-  <meta name="citation_publication_date" content="2023-01-20" />
-  <meta property="article:published_time" content="2023-01-20" />
-  <meta name="dc.modified" content="2023-01-20T22:00:28+00:00" />
-  <meta property="article:modified_time" content="2023-01-20T22:00:28+00:00" />
+  <meta name="dc.date" content="2023-01-24" />
+  <meta name="citation_publication_date" content="2023-01-24" />
+  <meta property="article:published_time" content="2023-01-24" />
+  <meta name="dc.modified" content="2023-01-24T02:17:08+00:00" />
+  <meta property="article:modified_time" content="2023-01-24T02:17:08+00:00" />
   <meta name="dc.language" content="en-US" />
   <meta name="citation_language" content="en-US" />
   <meta name="dc.relation.ispartof" content="Manubot" />
@@ -328,13 +328,13 @@
   <meta name="citation_fulltext_html_url" content="https://greenelab.github.io/covid19-review/" />
   <meta name="citation_pdf_url" content="https://greenelab.github.io/covid19-review/manuscript.pdf" />
   <link rel="alternate" type="application/pdf" href="https://greenelab.github.io/covid19-review/manuscript.pdf" />
-  <link rel="alternate" type="text/html" href="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/" />
-  <meta name="manubot_html_url_versioned" content="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/" />
-  <meta name="manubot_pdf_url_versioned" content="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf" />
+  <link rel="alternate" type="text/html" href="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/" />
+  <meta name="manubot_html_url_versioned" content="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/" />
+  <meta name="manubot_pdf_url_versioned" content="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf" />
   <meta property="og:type" content="article" />
   <meta property="twitter:card" content="summary_large_image" />
-  <meta property="og:image" content="https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png" />
-  <meta property="twitter:image" content="https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png" />
+  <meta property="og:image" content="https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png" />
+  <meta property="twitter:image" content="https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png" />
   <link rel="icon" type="image/png" sizes="192x192" href="https://manubot.org/favicon-192x192.png" />
   <link rel="mask-icon" href="https://manubot.org/safari-pinned-tab.svg" color="#ad1457" />
   <meta name="theme-color" content="#ad1457" />
@@ -349,11 +349,11 @@ <h1 class="title">SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and
 </header>
 <p><small><em>
 This manuscript
-(<a href="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/">permalink</a>)
+(<a href="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/">permalink</a>)
 was automatically generated
-from <a href="https://github.com/greenelab/covid19-review/tree/e1667739727de0e773dd80c8214fa4d6d6112cbd">greenelab/covid19-review@e166773</a>
-on January 20, 2023.
-It is also available as a <a href="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf">PDF</a>.
+from <a href="https://github.com/greenelab/covid19-review/tree/3668a38bb18729aea9d5298d870da0046319e291">greenelab/covid19-review@3668a38</a>
+on January 24, 2023.
+It is also available as a <a href="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf">PDF</a>.
 Snapshots of individual sections have been published <span class="citation" data-cites="GdZc4Yyd wgAGKcBj njpLhBui EM9YkiOF">(<a href="#ref-GdZc4Yyd" role="doc-biblioref">1</a>–<a href="#ref-EM9YkiOF" role="doc-biblioref">4</a>)</span> or posted as preprints <span class="citation" data-cites="hIxvVJ7F 1HWmcSB20 rjHK19Dr">(<a href="#ref-hIxvVJ7F" role="doc-biblioref">5</a>–<a href="#ref-rjHK19Dr" role="doc-biblioref">7</a>)</span>.
 </em></small></p>
 <!-- include the Font Awesome library, per: https://fontawesome.com/start -->
@@ -2228,9 +2228,9 @@ <h2 data-number="4.3" id="introduction-3"><span class="header-section-number">4.
 <h3 data-number="4.3.1" id="lessons-from-prior-hcov-outbreaks"><span class="header-section-number">4.3.1</span> Lessons from Prior HCoV Outbreaks</h3>
 <div id="fig:csse-deaths" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/csse/csse-deaths.png" alt="Figure 3: Cumulative global incidence of COVID-19 and SARS. As of January 18, 2023, 667,918,207 COVID-19 cases and 6,729,898 COVID-19 deaths had been reported worldwide since January 22, 2020. A total of 8,432 cases and 813 deaths were reported for SARS from March 17 to July 11, 2003. SARS-CoV-1 was officially contained on July 5, 2003, within 9 months of its appearance (730). In contrast, SARS-CoV-2 remains a significant global threat nearly two years after its emergence. COVID-19 data are from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University (731, 732). SARS data are from the WHO (733) and were obtained from a dataset on GitHub (734). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/csse/csse-deaths.png" alt="Figure 3: Cumulative global incidence of COVID-19 and SARS. As of January 22, 2023, 668,835,703 COVID-19 cases and 6,738,594 COVID-19 deaths had been reported worldwide since January 22, 2020. A total of 8,432 cases and 813 deaths were reported for SARS from March 17 to July 11, 2003. SARS-CoV-1 was officially contained on July 5, 2003, within 9 months of its appearance (730). In contrast, SARS-CoV-2 remains a significant global threat nearly two years after its emergence. COVID-19 data are from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University (731, 732). SARS data are from the WHO (733) and were obtained from a dataset on GitHub (734). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
 <figcaption aria-hidden="true"><span>Figure 3:</span> <strong>Cumulative global incidence of COVID-19 and SARS.</strong>
-As of January 18, 2023, 667,918,207 COVID-19 cases and 6,729,898 COVID-19 deaths had been reported worldwide since January 22, 2020.
+As of January 22, 2023, 668,835,703 COVID-19 cases and 6,738,594 COVID-19 deaths had been reported worldwide since January 22, 2020.
 A total of 8,432 cases and 813 deaths were reported for SARS from March 17 to July 11, 2003.
 SARS-CoV-1 was officially contained on July 5, 2003, within 9 months of its appearance <span class="citation" data-cites="bOegE5mX">(<a href="#ref-bOegE5mX" role="doc-biblioref">730</a>)</span>.
 In contrast, SARS-CoV-2 remains a significant global threat nearly two years after its emergence.
@@ -2278,7 +2278,7 @@ <h3 data-number="4.3.2" id="potential-approaches-to-the-treatment-of-covid-19"><
 Interventional clinical trials are currently investigating or have investigated a large number of possible therapeutics and combinations of therapeutics for the treatment of COVID-19 (Figure <a href="#fig:ebm-trials">4</a>).</p>
 <div id="fig:ebm-trials" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-trials.png" alt="Figure 4: COVID-19 clinical trials. Trials data are from the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker (739). As of December 31, 2020, there were 6,987 COVID-19 clinical trials of which 3,962 were interventional. The study types include only types used in at least five trials. Only interventional trials are analyzed in the figures depicting status, phase, and intervention. Of the interventional trials, 98 trials had reported results as of December 31, 2020. Recruitment status and trial phase are shown only for interventional trials in which the status or phase is recorded. Common interventions refers to interventions used in at least ten trials. Combinations of interventions, such as hydroxychloroquine with azithromycin, are tallied separately from the individual interventions. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-trials.png" alt="Figure 4: COVID-19 clinical trials. Trials data are from the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker (739). As of December 31, 2020, there were 6,987 COVID-19 clinical trials of which 3,962 were interventional. The study types include only types used in at least five trials. Only interventional trials are analyzed in the figures depicting status, phase, and intervention. Of the interventional trials, 98 trials had reported results as of December 31, 2020. Recruitment status and trial phase are shown only for interventional trials in which the status or phase is recorded. Common interventions refers to interventions used in at least ten trials. Combinations of interventions, such as hydroxychloroquine with azithromycin, are tallied separately from the individual interventions. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
 <figcaption aria-hidden="true"><span>Figure 4:</span> <strong>COVID-19 clinical trials.</strong>
 Trials data are from the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker <span class="citation" data-cites="SSbnPnzT">(<a href="#ref-SSbnPnzT" role="doc-biblioref">739</a>)</span>.
 As of December 31, 2020, there were 6,987 COVID-19 clinical trials of which 3,962 were interventional.
@@ -3348,7 +3348,7 @@ <h2 data-number="6.1" id="abstract-4"><span class="header-section-number">6.1</s
 Vaccine development programs that use established platforms have been undertaken in a much wider range of countries than those using nucleic-acid-based technologies, which have been led by wealthy Western countries.
 Therefore, these vaccine platforms, though less novel from a biotechnological standpoint, have proven to be extremely important to the management of SARS-CoV-2.</p>
 <h2 data-number="6.2" id="importance-4"><span class="header-section-number">6.2</span> Importance</h2>
-<p>As of January 18, 2023, there have been over 667,918,207 SARS-CoV-2 cases, and the virus has taken the lives of at least 6,729,898 people globally <span class="citation" data-cites="U1nCE851">(<a href="#ref-U1nCE851" role="doc-biblioref">732</a>)</span>.
+<p>As of January 22, 2023, there have been over 668,835,703 SARS-CoV-2 cases, and the virus has taken the lives of at least 6,738,594 people globally <span class="citation" data-cites="U1nCE851">(<a href="#ref-U1nCE851" role="doc-biblioref">732</a>)</span>.
 The development, production, and distribution of vaccines is imperative to saving lives, preventing illness, and reducing the economic and social burdens caused by the COVID-19 pandemic.
 Vaccines that use cutting-edge biotechnology have played an important role in mitigating the effects of SARS-CoV-2.
 However, more traditional methods of vaccine development that were refined throughout the twentieth century have been especially critical to increasing vaccine access worldwide.
@@ -3368,7 +3368,7 @@ <h2 data-number="6.3" id="introduction-4"><span class="header-section-number">6.
 We review vaccine technologies used for SARS-CoV-2 in two parts: here, the application of established vaccine development platforms to SARS-CoV-2, and separately, novel nucleic acid-based approaches <span class="citation" data-cites="rjHK19Dr">(<a href="#ref-rjHK19Dr" role="doc-biblioref">7</a>)</span>.</p>
 <p>Understanding vaccine development programs that are using well-established technologies is important for a global perspective on COVID-19.
 As of December 2, 2022, 50 SARS-CoV-2 vaccines have been approved for use in at least one country <span class="citation" data-cites="NdbXBY1h">(<a href="#ref-NdbXBY1h" role="doc-biblioref">1115</a>)</span>.
-A resource tracking the distribution of 28 vaccines indicates that, as of January 18, 2023, 13.0 billion doses have been administered across 223 countries <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span>.
+A resource tracking the distribution of 28 vaccines indicates that, as of January 22, 2023, 13.0 billion doses have been administered across 223 countries <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span>.
 Many of these vaccines use platforms that do not require information about the viral genome, with 20 developed using subunit and 11 using whole-virus approaches <span class="citation" data-cites="NdbXBY1h">(<a href="#ref-NdbXBY1h" role="doc-biblioref">1115</a>)</span>.
 The types of vaccines available varies widely throughout the world, as the process of developing and deploying a vaccine is complex and often requires coordination between government, industry, academia, and philanthropic entities <span class="citation" data-cites="plfPrQP7">(<a href="#ref-plfPrQP7" role="doc-biblioref">1117</a>)</span>.</p>
 <p>Another difference between prior global health crises and the COVID-19 pandemic is the way that vaccines are evaluated.
@@ -3563,16 +3563,16 @@ <h3 data-number="6.5.1" id="application-to-covid-19"><span class="header-section
 </table>
 </div>
 <p>Several whole-virus vaccines have been developed against COVID-19 and are available in countries around the world (Table <a href="#tbl:approved-whole-virus">2</a>).
-As of January 18, 2023, 10 vaccines developed with IWV technology are being distributed in 118 countries (Figure <a href="#fig:iwv-distrib">6</a>).
+As of January 22, 2023, 10 vaccines developed with IWV technology are being distributed in 118 countries (Figure <a href="#fig:iwv-distrib">6</a>).
 Evidence about the value of these vaccines to combat SARS-CoV-2 is available not only from clinical trials, but also from their roll-out following approval.
 Here, a major consideration has been that vaccines often lose efficacy as mutations accumulate in the epitopes of the circulating virus; IWV vaccines may be particularly affected in such cases <span class="citation" data-cites="K0Ltu31S">(<a href="#ref-K0Ltu31S" role="doc-biblioref">1127</a>)</span>.
 This loss of specificity over time is likely to be influenced by the evolution of the virus, and specifically by the rate of evolution in the region of the genome that codes for the antigenic spike protein.
 Here we review three vaccine development programs and their successes in a real-world setting.</p>
 <div id="fig:iwv-distrib" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/inactivated.png" alt="Figure 6: Worldwide availability of vaccines developed using inactivated whole viruses. This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 18, 2023. These data are retrieved from Our World in Data (532) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/inactivated.png" alt="Figure 6: Worldwide availability of vaccines developed using inactivated whole viruses. This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 22, 2023. These data are retrieved from Our World in Data (532) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
 <figcaption aria-hidden="true"><span>Figure 6:</span> <strong>Worldwide availability of vaccines developed using inactivated whole viruses.</strong>
-This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data <span class="citation" data-cites="3cPwqjhj">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>)</span> and plotted using geopandas <span class="citation" data-cites="iGEyNO42">(<a href="#ref-iGEyNO42" role="doc-biblioref">1170</a>)</span>.
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.</figcaption>
@@ -3659,7 +3659,7 @@ <h4 data-number="6.5.1.3" id="bharat-biotechs-covaxin"><span class="header-secti
 Based on a final enrollment of 25,798 people (~1:1 vaccine:placebo), overall VE against symptomatic COVID-19 was estimated at 77.8% and against severe disease and asymptomatic infection was reported as 93.4% and 63.6%, respectively <span class="citation" data-cites="1DD2pssEJ">(<a href="#ref-1DD2pssEJ" role="doc-biblioref">1218</a>)</span>.
 The vaccine was also reported to be well tolerated, with fewer severe events occurring in the Covaxin group (0.3%) than in the placebo group (0.5%) <span class="citation" data-cites="1DD2pssEJ">(<a href="#ref-1DD2pssEJ" role="doc-biblioref">1218</a>)</span>.
 One case of a serious AE potentially related to the vaccine, immune thrombocytopenic purpura, was reported, although this patient was seropositive for SARS-CoV-2 at the baseline observation point <span class="citation" data-cites="1DD2pssEJ">(<a href="#ref-1DD2pssEJ" role="doc-biblioref">1218</a>)</span>.
-As of January 19, 2023, Covaxin was approved for emergency use in 31 countries across Africa, Asia, Europe, and South America, including Guyana, India, Iran, Zimbabwe, Nepal, Mauritius, Mexico, Nepal, Paraguay, and the Philippines <span class="citation" data-cites="19tYVbg8H">(<a href="#ref-19tYVbg8H" role="doc-biblioref">1219</a>)</span>.</p>
+As of January 23, 2023, Covaxin was approved for emergency use in 31 countries across Africa, Asia, Europe, and South America, including Guyana, India, Iran, Zimbabwe, Nepal, Mauritius, Mexico, Nepal, Paraguay, and the Philippines <span class="citation" data-cites="19tYVbg8H">(<a href="#ref-19tYVbg8H" role="doc-biblioref">1219</a>)</span>.</p>
 <p>Like with all vaccines, the continued evolution of SARS-CoV-2 poses a challenge to the effectiveness of Covaxin.
 In this case, the phase III clinical trial did evaluate the efficacy of Covaxin in response to variants circulating in mid-to-late 2020 <span class="citation" data-cites="1DD2pssEJ">(<a href="#ref-1DD2pssEJ" role="doc-biblioref">1218</a>)</span>.
 In agreement with previous studies demonstrating sera from individuals vaccinated with Covaxin efficiently neutralized the Alpha variant (B.1.1.7) and the Delta variant (B.1.617.2) <span class="citation" data-cites="lr7INjf6 UYE3NvU4 IvOEe7bV">(<a href="#ref-lr7INjf6" role="doc-biblioref">1220</a>–<a href="#ref-IvOEe7bV" role="doc-biblioref">1222</a>)</span>, the phase III trial reported a 65.2% efficacy against the Delta variant (B.1.617.2) <span class="citation" data-cites="1DD2pssEJ">(<a href="#ref-1DD2pssEJ" role="doc-biblioref">1218</a>)</span>.
@@ -3844,12 +3844,12 @@ <h3 data-number="6.6.1" id="application-to-covid-19-1"><span class="header-secti
 </div>
 <p>The development of subunit vaccines against SARS-CoV-2 is a remarkable achievement given the short period of time since the emergence of SARS-CoV-2 in late 2019, particularly considering these types of vaccines have not played a major role in previous pandemics compared to LAV and IWV vaccines.
 More than 20 protein subunit vaccines from companies such as Sanofi/GlaxoSmithKline, Nanogen, and the Serum Institute of India have entered clinical trials for COVID-19 since the beginning of the pandemic <span class="citation" data-cites="8dSIiLCt">(<a href="#ref-8dSIiLCt" role="doc-biblioref">1293</a>)</span>, 20 have been approved, and at least 9 are being administered worldwide <span class="citation" data-cites="sRy6js2o NdbXBY1h">(<a href="#ref-NdbXBY1h" role="doc-biblioref">1115</a>, <a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span> (Table <a href="#tbl:approved-subunit">3</a>).
-As of January 18, 2023, protein subunit vaccines are being distributed in at least 42 countries (Figure <a href="#fig:ps-distrib">7</a>).</p>
+As of January 22, 2023, protein subunit vaccines are being distributed in at least 42 countries (Figure <a href="#fig:ps-distrib">7</a>).</p>
 <div id="fig:ps-distrib" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/protein_subunit.png" alt="Figure 7: Worldwide availability of vaccines developed using protein subunit. This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 18, 2023. These data are retrieved from Our World in Data (532, 1116) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/protein_subunit.png" alt="Figure 7: Worldwide availability of vaccines developed using protein subunit. This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 22, 2023. These data are retrieved from Our World in Data (532, 1116) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
 <figcaption aria-hidden="true"><span>Figure 7:</span> <strong>Worldwide availability of vaccines developed using protein subunit.</strong>
-This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data <span class="citation" data-cites="3cPwqjhj sRy6js2o">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>, <a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span> and plotted using geopandas <span class="citation" data-cites="iGEyNO42">(<a href="#ref-iGEyNO42" role="doc-biblioref">1170</a>)</span>.
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.</figcaption>
@@ -3857,12 +3857,12 @@ <h3 data-number="6.6.1" id="application-to-covid-19-1"><span class="header-secti
 </div>
 <p>VLP vaccines have not progressed as rapidly.
 Programs seeking to develop VLP vaccines have used either the full-length S protein or the RBD of the S protein specifically as an antigen, although some use several different SARS-CoV-2 proteins <span class="citation" data-cites="1FfwyYaj7">(<a href="#ref-1FfwyYaj7" role="doc-biblioref">1254</a>)</span>.
-As of January 18, 2023, only one VLP was available in one country (Canada) <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span>.<!--Canada/Covifenz info is hardcoded--></p>
+As of January 22, 2023, only one VLP was available in one country (Canada) <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span>.<!--Canada/Covifenz info is hardcoded--></p>
 <div id="fig:vlp-distrib" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/VLP.png" alt="Figure 8: Worldwide availability of vaccines developed with VLPs. This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 18, 2023. These data are retrieved from Our World in Data (532) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/VLP.png" alt="Figure 8: Worldwide availability of vaccines developed with VLPs. This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 22, 2023. These data are retrieved from Our World in Data (532) and plotted using geopandas (1170). The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country. See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily." />
 <figcaption aria-hidden="true"><span>Figure 8:</span> <strong>Worldwide availability of vaccines developed with VLPs.</strong>
-This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data <span class="citation" data-cites="3cPwqjhj">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>)</span> and plotted using geopandas <span class="citation" data-cites="iGEyNO42">(<a href="#ref-iGEyNO42" role="doc-biblioref">1170</a>)</span>.
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.</figcaption>
@@ -3997,8 +3997,8 @@ <h2 data-number="6.7" id="global-vaccine-status-and-distribution"><span class="h
 <p>The unprecedented deployment of COVID-19 vaccines in under a year from the identification of SARS-CoV-2 led to a new challenge: the formation of rapid global vaccine production and distribution plans.
 The development of vaccines is costly and complicated, but vaccine distribution can be just as challenging.
 Logistical considerations such as transport, storage, equipment (e.g., syringes), the workforce to administer the vaccines, and a continual supply from the manufacturers to meet global demands all must be accounted for and vary globally due to economic, geographic, and sociopolitical reasons <span class="citation" data-cites="RG0vzlcE 19CWe6pdS d0kUYq5Z">(<a href="#ref-RG0vzlcE" role="doc-biblioref">1361</a>–<a href="#ref-d0kUYq5Z" role="doc-biblioref">1363</a>)</span>.
-As of January 12, 2023, at least 13.0 billion vaccine doses had been administered in at least 223 countries worldwide using 28 different vaccines <span class="citation" data-cites="3cPwqjhj">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>)</span>.&gt;
-The daily global vaccination rate at this time was 260.0 per million.</p>
+As of January 16, 2023, at least 13.0 billion vaccine doses had been administered in at least 223 countries worldwide using 28 different vaccines <span class="citation" data-cites="3cPwqjhj">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>)</span>.&gt;
+The daily global vaccination rate at this time was 251.0 per million.</p>
 <p>However, the distribution of these doses is not uniform around the globe.
 Latin America leads world vaccination rates with at least 82% of individuals in this region receiving one vaccine dose followed by the U.S. and Canada (81%), Asia-Pacific (81%), Europe (70%), the Middle East (58%), and Africa with only 33% as of November 2022 <span class="citation" data-cites="dfl5iCJI">(<a href="#ref-dfl5iCJI" role="doc-biblioref">1364</a>)</span>.
 It is estimated that only ~25% of individuals in low- and middle-income countries have received one vaccine dose <span class="citation" data-cites="cWMPXfju sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>, <a href="#ref-cWMPXfju" role="doc-biblioref">1365</a>)</span>.
@@ -4015,9 +4015,9 @@ <h2 data-number="6.7" id="global-vaccine-status-and-distribution"><span class="h
 Therefore, vaccine development programs that utilized established vaccine technologies have played a critical role in providing protection against SARS-CoV at the global level.</p>
 <div id="fig:gdpscatter" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/OWID_doseTypebyGDP.png" alt="Figure 9: Vaccine Distribution across Platform Types as a Function of GDP. The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 18, 2023, by platform type, is shown as a function of GDP. These data are retrieved from Our World in Data (532, 1116) and plotted using the Python package plotnine (1371). Lines show a general trend in the data and are drawn using geom_smooth (1372). The list of countries included in the dataset is available from OWID (1373). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Axes are not scaled per capita because both variables are modulated by population size." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/OWID_doseTypebyGDP.png" alt="Figure 9: Vaccine Distribution across Platform Types as a Function of GDP. The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 22, 2023, by platform type, is shown as a function of GDP. These data are retrieved from Our World in Data (532, 1116) and plotted using the Python package plotnine (1371). Lines show a general trend in the data and are drawn using geom_smooth (1372). The list of countries included in the dataset is available from OWID (1373). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Axes are not scaled per capita because both variables are modulated by population size." />
 <figcaption aria-hidden="true"><span>Figure 9:</span> <strong>Vaccine Distribution across Platform Types as a Function of GDP.</strong>
-The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 18, 2023, by platform type, is shown as a function of GDP.
+The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 22, 2023, by platform type, is shown as a function of GDP.
 These data are retrieved from Our World in Data <span class="citation" data-cites="3cPwqjhj sRy6js2o">(<a href="#ref-3cPwqjhj" role="doc-biblioref">532</a>, <a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span> and plotted using the Python package plotnine <span class="citation" data-cites="L5wrzuPV">(<a href="#ref-L5wrzuPV" role="doc-biblioref">1371</a>)</span>.
 Lines show a general trend in the data and are drawn using geom_smooth <span class="citation" data-cites="48MbU9B0">(<a href="#ref-48MbU9B0" role="doc-biblioref">1372</a>)</span>.
 The list of countries included in the dataset is available from OWID <span class="citation" data-cites="FCTCkZoZ">(<a href="#ref-FCTCkZoZ" role="doc-biblioref">1373</a>)</span>.
@@ -4516,9 +4516,9 @@ <h4 data-number="8.8.2.1" id="prior-applications-1"><span class="header-section-
 <h4 data-number="8.8.2.2" id="application-to-covid-19-2"><span class="header-section-number">8.8.2.2</span> Application to COVID-19</h4>
 <div id="fig:nrvv-distrib" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/non_replicating_viral_vector.png" alt="Figure 11: Worldwide availability of vaccines developed using non-replicating viral vectors. This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 18, 2023. These data are retrieved from Our World in Data (1116) and plotted using geopandas (1170). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Note that this figure draws from a different data source than Table 4 and does not necessarily include data for every vaccine developed within this category." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/non_replicating_viral_vector.png" alt="Figure 11: Worldwide availability of vaccines developed using non-replicating viral vectors. This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 22, 2023. These data are retrieved from Our World in Data (1116) and plotted using geopandas (1170). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Note that this figure draws from a different data source than Table 4 and does not necessarily include data for every vaccine developed within this category." />
 <figcaption aria-hidden="true"><span>Figure 11:</span> <strong>Worldwide availability of vaccines developed using non-replicating viral vectors.</strong><!--As a general comment on the choropleths, is there any way to increase resolution. Hard to see what’s happening in Europe and south east Asia.--><!--Updated from 300 to 600 after this comment in #1169, let's see if it helped-->
-This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span> and plotted using geopandas <span class="citation" data-cites="iGEyNO42">(<a href="#ref-iGEyNO42" role="doc-biblioref">1170</a>)</span>.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
 Note that this figure draws from a different data source than Table <a href="#tbl:approved-DNA">4</a> and does not necessarily include data for every vaccine developed within this category.</figcaption>
@@ -4541,7 +4541,7 @@ <h4 data-number="8.8.2.2" id="application-to-covid-19-2"><span class="header-sec
 The JNJ-78436735 candidate was selected for its favorable immunogenicity profile and ease of manufacturability <span class="citation" data-cites="10UC562ga gOOBv1MD HmMIiIv2 EpOXYGt4">(<a href="#ref-10UC562ga" role="doc-biblioref">1485</a>, <a href="#ref-gOOBv1MD" role="doc-biblioref">1563</a>–<a href="#ref-EpOXYGt4" role="doc-biblioref">1565</a>)</span> and was found to confer protection against SARS-CoV-2 in macaques even after six months <span class="citation" data-cites="HGVDPMLm">(<a href="#ref-HGVDPMLm" role="doc-biblioref">1566</a>)</span>.
 The one- versus two-dose regimen was then tested in volunteers through a phase I/IIa trial <span class="citation" data-cites="pWf2T8J8 69GoEX0X">(<a href="#ref-pWf2T8J8" role="doc-biblioref">1562</a>, <a href="#ref-69GoEX0X" role="doc-biblioref">1567</a>)</span>.
 A major difference between this vaccine and the other two in this category is that the S protein immunogen is stabilized in its prefusion conformation, while in the Sputnik V and AstraZeneca vaccines it is not.</p>
-<p>As of January 18, 2023, data describing the distribution of 5 viral-vectored vaccines in 202 countries are available (Figure <a href="#fig:nrvv-distrib">11</a>).
+<p>As of January 22, 2023, data describing the distribution of 5 viral-vectored vaccines in 202 countries are available (Figure <a href="#fig:nrvv-distrib">11</a>).
 ChAdOx1 nCoV-19 was first approved for emergency use on December 30, 2020 in the U.K. <span class="citation" data-cites="1A7PjhDDR">(<a href="#ref-1A7PjhDDR" role="doc-biblioref">1568</a>)</span>.
 Sputnik V was available soon after, and early as January 2021, Sputnik V had been administered to 1.5 million Russians <span class="citation" data-cites="X5LkVfY6">(<a href="#ref-X5LkVfY6" role="doc-biblioref">1569</a>)</span> and began distributing doses to other countries within Europe such as Belarus, Bosnia-Herzegovina, Hungary, San Marino, Serbia, and Slovakia <span class="citation" data-cites="16LczMwFO Z0V7NK7Y 16GYKbrOq">(<a href="#ref-16LczMwFO" role="doc-biblioref">1570</a>–<a href="#ref-16GYKbrOq" role="doc-biblioref">1572</a>)</span>.</p>
 <h4 data-number="8.8.2.3" id="trial-estimates-of-safety-and-efficacy"><span class="header-section-number">8.8.2.3</span> Trial Estimates of Safety and Efficacy</h4>
@@ -4690,12 +4690,12 @@ <h4 data-number="8.9.0.2" id="application-to-covid-19-3"><span class="header-sec
 The first was Pfizer/BioNTech’s BNT162b2, which contains the full prefusion stabilized, membrane-anchored SARS-CoV-2 Spike protein in a vaccine formulation based on modified mRNA (modRNA) technology <span class="citation" data-cites="1CsCQi9wT 10VyxCgQU">(<a href="#ref-1CsCQi9wT" role="doc-biblioref">1620</a>, <a href="#ref-10VyxCgQU" role="doc-biblioref">1621</a>)</span>.
 The second mRNA vaccine, mRNA-1273 developed by ModernaTX, is comprised by a conventional LNP-encapsulated RNA encoding a full-length prefusion stabilized S protein for SARS-CoV-2 <span class="citation" data-cites="Biu1CQeQ">(<a href="#ref-Biu1CQeQ" role="doc-biblioref">1622</a>)</span>.
 The vaccine candidates developed against SARS-CoV-2 using mRNA vectors utilize similar principles and technologies, although there are slight differences in implementation among candidates such as the formulation of the platform and the specific components of the Spike protein encapsulated (e.g., the full Spike protein vs. the RBD alone) <span class="citation" data-cites="suRY1e0N">(<a href="#ref-suRY1e0N" role="doc-biblioref">1623</a>)</span>.
-As of January 18, 2023, 2 mRNA vaccines are available in 169 countries (Figure <a href="#fig:mRNA-distrib">12</a>).</p>
+As of January 22, 2023, 2 mRNA vaccines are available in 169 countries (Figure <a href="#fig:mRNA-distrib">12</a>).</p>
 <div id="fig:mRNA-distrib" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/RNA.png" alt="Figure 12: Worldwide availability of vaccines developed using mRNA. This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 18, 2023. These data are retrieved from Our World in Data (1116) and plotted using geopandas (1170). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Note that this figure draws from a different data source than Table 5 and does not necessarily include data for every vaccine developed within this category." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/RNA.png" alt="Figure 12: Worldwide availability of vaccines developed using mRNA. This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 22, 2023. These data are retrieved from Our World in Data (1116) and plotted using geopandas (1170). See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily. Note that this figure draws from a different data source than Table 5 and does not necessarily include data for every vaccine developed within this category." />
 <figcaption aria-hidden="true"><span>Figure 12:</span> <strong>Worldwide availability of vaccines developed using mRNA.</strong>
-This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data <span class="citation" data-cites="sRy6js2o">(<a href="#ref-sRy6js2o" role="doc-biblioref">1116</a>)</span> and plotted using geopandas <span class="citation" data-cites="iGEyNO42">(<a href="#ref-iGEyNO42" role="doc-biblioref">1170</a>)</span>.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
 Note that this figure draws from a different data source than Table <a href="#tbl:approved-RNA">5</a> and does not necessarily include data for every vaccine developed within this category.</figcaption>
@@ -5616,7 +5616,7 @@ <h3 data-number="11.3.4" id="access-to-and-representation-in-clinical-trials"><s
 Trials that recruit across multiple countries do appear to broaden geographic representation, but these trials seem to be heavily dominated by the United States and European Union.</p>
 <div id="fig:ebm-map" class="fignos">
 <figure>
-<img src="https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-map.png" alt="Figure 13: Geographic distribution of COVID-19 clinical trials. The density of clinical trials is reported at the country level. As of December 31, 2020, there are 6,987 trials in the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker (739), of which 3,962 are interventional. The top figure demonstrates the density of interventional trials recruiting only from a singular country, while the bottom shows the distribution of recruitment for interventional trials that involve more than one country." />
+<img src="https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-map.png" alt="Figure 13: Geographic distribution of COVID-19 clinical trials. The density of clinical trials is reported at the country level. As of December 31, 2020, there are 6,987 trials in the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker (739), of which 3,962 are interventional. The top figure demonstrates the density of interventional trials recruiting only from a singular country, while the bottom shows the distribution of recruitment for interventional trials that involve more than one country." />
 <figcaption aria-hidden="true"><span>Figure 13:</span> <strong>Geographic distribution of COVID-19 clinical trials.</strong>
 The density of clinical trials is reported at the country level.
 As of December 31, 2020, there are 6,987 trials in the University of Oxford Evidence-Based Medicine Data Lab’s COVID-19 TrialsTracker <span class="citation" data-cites="SSbnPnzT">(<a href="#ref-SSbnPnzT" role="doc-biblioref">739</a>)</span>, of which 3,962 are interventional.
@@ -9998,7 +9998,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1152. </div><div class="csl-right-inline">BCG Vaccine for Health Care Workers as Defense Against COVID 19 - Full Text View - ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT04348370">https://clinicaltrials.gov/ct2/show/NCT04348370</a>. Retrieved 8 February 2021.</div>
 </div>
 <div id="ref-OPhELmwI" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1153. </div><div class="csl-right-inline">Codagenix Inc: COVI-VAC – COVID19 Vaccine Tracker. <a href="https://covid19.trackvaccines.org/vaccines/59/">https://covid19.trackvaccines.org/vaccines/59/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1153. </div><div class="csl-right-inline">Codagenix Inc: COVI-VAC – COVID19 Vaccine Tracker. <a href="https://covid19.trackvaccines.org/vaccines/59/">https://covid19.trackvaccines.org/vaccines/59/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-bgKUtUIL" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1154. </div><div class="csl-right-inline">Robert-Guroff M. 2007. <a href="https://doi.org/10.1016/j.copbio.2007.10.010">Replicating and non-replicating viral vectors for vaccine development</a>. Current Opinion in Biotechnology 18:546–556.</div>
@@ -10250,7 +10250,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1236. </div><div class="csl-right-inline">Thiagarajan K. 2022. <a href="https://doi.org/10.1136/bmj.o902">Covid-19: WHO suspends supplies of India’s Covaxin through UN agencies</a>. BMJ o902.</div>
 </div>
 <div id="ref-1B0oIysG0" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1237. </div><div class="csl-right-inline">2022. FDA lifts hold on Bharat Biotech's Covaxin clinical trials in US. Business Today. <a href="https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24">https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1237. </div><div class="csl-right-inline">2022. FDA lifts hold on Bharat Biotech's Covaxin clinical trials in US. Business Today. <a href="https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24">https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-1Fybz4oKI" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1238. </div><div class="csl-right-inline">Moir NL. 2020. <a href="https://doi.org/10.1163/25895893-bja10009">To Boldly Remember Where We Have Already Been</a>. J Appl Hist 2:17–35.</div>
@@ -10424,7 +10424,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1294. </div><div class="csl-right-inline">Wang M, Jiang S, Wang Y. 2016. <a href="https://doi.org/10.1080/21655979.2016.1191707">Recent advances in the production of recombinant subunit vaccines in Pichia pastoris</a>. Bioengineered 7:155–165.</div>
 </div>
 <div id="ref-uobXLbLj" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1295. </div><div class="csl-right-inline">The Novavax vaccine against COVID-19: What you need to know. <a href="https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know">https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1295. </div><div class="csl-right-inline">The Novavax vaccine against COVID-19: What you need to know. <a href="https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know">https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-dMLXxGAI" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1296. </div><div class="csl-right-inline">Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. 2020. <a href="https://doi.org/10.1056/nejmoa2026920">Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</a>. N Engl J Med 383:2320–2332.</div>
@@ -10448,7 +10448,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1302. </div><div class="csl-right-inline">Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F. 2021. <a href="https://doi.org/10.1101/2021.10.05.21264567">Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico</a>. Cold Spring Harbor Laboratory.</div>
 </div>
 <div id="ref-Z8b1NywM" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1303. </div><div class="csl-right-inline">Novavax missed its global moonshot but is angling to win over mRNA defectors. <a href="https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling">https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1303. </div><div class="csl-right-inline">Novavax missed its global moonshot but is angling to win over mRNA defectors. <a href="https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling">https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-ORkwMcrn" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1304. </div><div class="csl-right-inline">Tinari S, Riva C. 2021. <a href="https://doi.org/10.1136/bmj.n2965">Covid-19: Whatever happened to the Novavax vaccine?</a> BMJ n2965.</div>
@@ -10457,13 +10457,13 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1305. </div><div class="csl-right-inline">Price WN II, Rai AK, Minssen T. 2020. <a href="https://doi.org/10.1126/science.abc9588">Knowledge transfer for large-scale vaccine manufacturing</a>. Science 369:912–914.</div>
 </div>
 <div id="ref-Fw20AJGb" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1306. </div><div class="csl-right-inline">‘They rushed the process’: Vaccine maker’s woes hamper global inoculation campaign. POLITICO. <a href="https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298">https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1306. </div><div class="csl-right-inline">‘They rushed the process’: Vaccine maker’s woes hamper global inoculation campaign. POLITICO. <a href="https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298">https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-5QLauLQN" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1307. </div><div class="csl-right-inline">Kimball S. Novavax confident Covid vaccine will receive FDA authorization in June after delays. CNBC. <a href="https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html">https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1307. </div><div class="csl-right-inline">Kimball S. Novavax confident Covid vaccine will receive FDA authorization in June after delays. CNBC. <a href="https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html">https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-rD5VxtBn" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1308. </div><div class="csl-right-inline">WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. <a href="https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries">https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1308. </div><div class="csl-right-inline">WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. <a href="https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries">https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-q3wIcP4d" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1309. </div><div class="csl-right-inline">Novavax COVID-19 vaccine Nuvaxovid approved by MHRA. GOVUK. <a href="https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra">https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra</a>. Retrieved 5 December 2022.</div>
@@ -10517,7 +10517,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1325. </div><div class="csl-right-inline">Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. 2022. <a href="https://doi.org/10.1016/j.eclinm.2022.101383">Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)</a>. eClinicalMedicine 46:101383.</div>
 </div>
 <div id="ref-dDFVQ4qj" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1326. </div><div class="csl-right-inline">Cuba's Abdala COVID-19 vaccine enters phase 3 clinical trial - Xinhua | English.news.cn. <a href="http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm">http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1326. </div><div class="csl-right-inline">Cuba's Abdala COVID-19 vaccine enters phase 3 clinical trial - Xinhua | English.news.cn. <a href="http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm">http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-Efkzneb" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1327. </div><div class="csl-right-inline">Reuters. 2021. <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21/">Cuba says Abdala vaccine 92.28% effective against coronavirus</a>. Reuters.</div>
@@ -10526,7 +10526,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1328. </div><div class="csl-right-inline">2021. <a href="https://www.granma.cu/cuba/2021-06-21/abdala-con-tres-dosis-tiene-una-eficacia-de-9228-porciento-21-06-2021-21-06-01">Abdala, con tres dosis, tiene una eficacia de 92,28 %</a>.</div>
 </div>
 <div id="ref-12ASOHNL" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1329. </div><div class="csl-right-inline">Staff O. 2021. How was the efficacy of the Cuban COVID-19 vaccine candidates calculated? OnCubaNews English. <a href="https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/">https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1329. </div><div class="csl-right-inline">Staff O. 2021. How was the efficacy of the Cuban COVID-19 vaccine candidates calculated? OnCubaNews English. <a href="https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/">https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-TPxaU9zy" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1330. </div><div class="csl-right-inline">2021. Aprueba el CECMED el Autorizo de Uso de Emergencia del candidato vacunal cubano ABDALA. <a href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala">https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala</a>. Retrieved 22 December 2022.</div>
@@ -10558,16 +10558,16 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1338. </div><div class="csl-right-inline">Serrano-Barrera OR, Bello-Rodríguez MM, Pupo-Rodríguez OL, Robinson-Agramonte M de los A, Pérez O. 2022. <a href="https://revzoilomarinello.sld.cu/index.php/zmv/article/view/2999">Variantes ómicron y delta de SARS-CoV-2 conservan epítopes presentes en vacunas cubanas anti-covid-19 Abdala y Soberana</a>. Revista Electrónica Dr Zoilo E Marinello Vidaurreta 47.</div>
 </div>
 <div id="ref-xOCyDuHP" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1339. </div><div class="csl-right-inline">Staff O. 2021. Cuba to apply booster doses of its COVID-19 vaccines. OnCubaNews English. <a href="https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/">https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1339. </div><div class="csl-right-inline">Staff O. 2021. Cuba to apply booster doses of its COVID-19 vaccines. OnCubaNews English. <a href="https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/">https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-dYUfQjoS" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1340. </div><div class="csl-right-inline">Meredith S. Why Cuba's extraordinary Covid vaccine success could provide the best hope for low-income countries. CNBC. <a href="https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html">https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1340. </div><div class="csl-right-inline">Meredith S. Why Cuba's extraordinary Covid vaccine success could provide the best hope for low-income countries. CNBC. <a href="https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html">https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-63kJzd7x" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1341. </div><div class="csl-right-inline">Frank M, Sherwood D. 2021. <a href="https://www.reuters.com/world/americas/cuba-fast-track-boosters-omicron-looms-2021-12-29/">Cuba to fast-track boosters as Omicron looms</a>. Reuters.</div>
 </div>
 <div id="ref-gZZJk4ud" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1342. </div><div class="csl-right-inline">Cuba COVID - Coronavirus Statistics - Worldometer. <a href="https://www.worldometers.info/coronavirus/country/cuba">https://www.worldometers.info/coronavirus/country/cuba</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1342. </div><div class="csl-right-inline">Cuba COVID - Coronavirus Statistics - Worldometer. <a href="https://www.worldometers.info/coronavirus/country/cuba">https://www.worldometers.info/coronavirus/country/cuba</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-1HEqhSLwM" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1343. </div><div class="csl-right-inline">Taylor L. 2021. <a href="https://doi.org/10.1136/bmj.n1912">Why Cuba developed its own covid vaccine—and what happened next</a>. BMJ n1912.</div>
@@ -10603,13 +10603,13 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1353. </div><div class="csl-right-inline">Chen Q, Lai H. 2013. <a href="https://doi.org/10.4161/hv.22218">Plant-derived virus-like particles as vaccines</a>. Human Vaccines &amp;amp; Immunotherapeutics 9:26–49.</div>
 </div>
 <div id="ref-1FqN12Yxh" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1354. </div><div class="csl-right-inline">News · PL·C. Big Tobacco's divestment from Quebec's Medicago 'a step in the right direction' for its COVID vaccine | CBC News. CBC. <a href="https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103">https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1354. </div><div class="csl-right-inline">News · PL·C. Big Tobacco's divestment from Quebec's Medicago 'a step in the right direction' for its COVID vaccine | CBC News. CBC. <a href="https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103">https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-IZ0arNZC" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1355. </div><div class="csl-right-inline">2022. COVID-19 vaccine: Canadian Immunization Guide. <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html</a>. Retrieved 22 December 2022.</div>
 </div>
 <div id="ref-UmRMCPZW" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1356. </div><div class="csl-right-inline">News releases. Medicago. <a href="https://medicago.com/en/news-releases/">https://medicago.com/en/news-releases/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1356. </div><div class="csl-right-inline">News releases. Medicago. <a href="https://medicago.com/en/news-releases/">https://medicago.com/en/news-releases/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-htCBRryz" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1357. </div><div class="csl-right-inline">Mohammadi M, Shayestehpour M, Mirzaei H. 2021. <a href="https://doi.org/10.1016/j.bjid.2021.101606">The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines</a>. The Brazilian Journal of Infectious Diseases 25:101606.</div>
@@ -10702,10 +10702,10 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1386. </div><div class="csl-right-inline">Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, Macdonald B, Dattani S, Beltekian D, Ortiz-Ospina E, Roser M. 2020. <a href="https://ourworldindata.org/covid-vaccination-policy">Coronavirus Pandemic (COVID-19)</a>. Our World in Data.</div>
 </div>
 <div id="ref-T5hm2GMj" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1387. </div><div class="csl-right-inline">Ferran M. CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally. The Conversation. <a href="http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672">http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1387. </div><div class="csl-right-inline">Ferran M. CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally. The Conversation. <a href="http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672">http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-RueOviyL" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1388. </div><div class="csl-right-inline">Biological E Limited: Corbevax – COVID19 Vaccine Tracker. <a href="https://covid19.trackvaccines.org/vaccines/54/">https://covid19.trackvaccines.org/vaccines/54/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1388. </div><div class="csl-right-inline">Biological E Limited: Corbevax – COVID19 Vaccine Tracker. <a href="https://covid19.trackvaccines.org/vaccines/54/">https://covid19.trackvaccines.org/vaccines/54/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-ZCOfVmLC" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1389. </div><div class="csl-right-inline">James ER. 2021. <a href="https://doi.org/10.1093/inthealth/ihab010">Disrupting vaccine logistics</a>. International Health 13:211–214.</div>
@@ -10717,7 +10717,7 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1391. </div><div class="csl-right-inline">Sguazzin A. 2021. <a href="https://www.bloomberg.com/news/articles/2021-01-03/pfizer-to-supply-african-health-care-workers-with-vaccines">Africa Left With Few Options for Vaccines, South Africa Says</a>. Bloomberg.</div>
 </div>
 <div id="ref-LwA7POre" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1392. </div><div class="csl-right-inline">COVAX: ensuring global equitable access to COVID-19 vaccines. <a href="https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines">https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1392. </div><div class="csl-right-inline">COVAX: ensuring global equitable access to COVID-19 vaccines. <a href="https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines">https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-h68ER2wh" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1393. </div><div class="csl-right-inline">Bajaj SS, Maki L, Stanford FC. 2022. <a href="https://doi.org/10.1016/s0140-6736(22)00328-2">Vaccine apartheid: global cooperation and equity</a>. The Lancet 399:1452–1453.</div>
@@ -10729,13 +10729,13 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1395. </div><div class="csl-right-inline">Grenfell RFQ, Oyeyemi OT. 2022. <a href="https://doi.org/10.1080/20477724.2022.2091862">Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study</a>. Pathogens and Global Health 1–15.</div>
 </div>
 <div id="ref-Pjo8Db92" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1396. </div><div class="csl-right-inline">Taylor A. 2022. <a href="https://www.washingtonpost.com/world/2021/12/10/covax-doses-delivered/">Covax promised 2 billion vaccine doses to help the world’s neediest in 2021. It won’t deliver even half that.</a> Washington Post.</div>
+<div class="csl-left-margin">1396. </div><div class="csl-right-inline">. <a href="https://www.washingtonpost.com/world/2021/12/10/covax-doses-delivered">https://www.washingtonpost.com/world/2021/12/10/covax-doses-delivered</a>.</div>
 </div>
 <div id="ref-1683Ay0Ma" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1397. </div><div class="csl-right-inline">Ten health issues WHO will tackle this year. <a href="https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019">https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1397. </div><div class="csl-right-inline">Ten health issues WHO will tackle this year. <a href="https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019">https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-vgBdaJfl" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1398. </div><div class="csl-right-inline">Lopes L, 2021. 2021. KFF COVID-19 Vaccine Monitor: January 2021. KFF. <a href="https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/">https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1398. </div><div class="csl-right-inline">Lopes L, 2021. 2021. KFF COVID-19 Vaccine Monitor: January 2021. KFF. <a href="https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/">https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-9WzhBzsN" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1399. </div><div class="csl-right-inline">Rosenbaum L. 2021. <a href="https://doi.org/10.1056/nejmms2101220">Escaping Catch-22 — Overcoming Covid Vaccine Hesitancy</a>. N Engl J Med 384:1367–1371.</div>
@@ -10791,16 +10791,16 @@ <h2 class="page_break_before" data-number="13.4" id="references"><span class="he
 <div class="csl-left-margin">1415. </div><div class="csl-right-inline">Jacobson RM, St. Sauver JL, Finney Rutten LJ. 2015. <a href="https://doi.org/10.1016/j.mayocp.2015.09.006">Vaccine Hesitancy</a>. Mayo Clinic Proceedings 90:1562–1568.</div>
 </div>
 <div id="ref-1ADXp4JiF" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1416. </div><div class="csl-right-inline">What sets apart Novavax option from other COVID-19 vaccines. American Medical Association. <a href="https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines">https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1416. </div><div class="csl-right-inline">What sets apart Novavax option from other COVID-19 vaccines. American Medical Association. <a href="https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines">https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-1HJpEx8e7" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1417. </div><div class="csl-right-inline">RUPP DMBAR. Novavax COVID vaccine is for those hesitant to get vaccinated. The Daily News. <a href="https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html">https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1417. </div><div class="csl-right-inline">RUPP DMBAR. Novavax COVID vaccine is for those hesitant to get vaccinated. The Daily News. <a href="https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html">https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-13O5dayXS" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1418. </div><div class="csl-right-inline">Rubin R. 2022. <a href="https://doi.org/10.1001/jama.2022.13661">Despite Its Fan Base, Newly Authorized “Traditional” Novavax COVID-19 Vaccine Is Having Trouble Gaining a Foothold in the US</a>. JAMA 328:1026.</div>
 </div>
 <div id="ref-MMu5x58p" class="csl-entry" role="doc-biblioentry">
-<div class="csl-left-margin">1419. </div><div class="csl-right-inline">Constantino AK. Novavax's new Covid vaccine is perfect for people scared of mRNA tech—but it won't win over the unvaccinated. CNBC. <a href="https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html">https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html</a>. Retrieved 20 January 2023.</div>
+<div class="csl-left-margin">1419. </div><div class="csl-right-inline">Constantino AK. Novavax's new Covid vaccine is perfect for people scared of mRNA tech—but it won't win over the unvaccinated. CNBC. <a href="https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html">https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html</a>. Retrieved 23 January 2023.</div>
 </div>
 <div id="ref-rWUeWzwm" class="csl-entry" role="doc-biblioentry">
 <div class="csl-left-margin">1420. </div><div class="csl-right-inline">Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR. 2021. <a href="https://doi.org/10.1016/j.vaccine.2021.05.099">Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization</a>. Vaccine 39:4013–4024.</div>
diff --git a/manuscript.md b/manuscript.md
index 58b11072b..12fc3adf1 100644
--- a/manuscript.md
+++ b/manuscript.md
@@ -6,7 +6,7 @@ keywords:
 - pandemic
 - viral infection
 lang: en-US
-date-meta: '2023-01-20'
+date-meta: '2023-01-24'
 author-meta:
 - Halie M. Rando
 - Casey S. Greene
@@ -73,11 +73,11 @@ header-includes: |
   <meta name="citation_title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
   <meta property="og:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
   <meta property="twitter:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />
-  <meta name="dc.date" content="2023-01-20" />
-  <meta name="citation_publication_date" content="2023-01-20" />
-  <meta property="article:published_time" content="2023-01-20" />
-  <meta name="dc.modified" content="2023-01-20T22:00:28+00:00" />
-  <meta property="article:modified_time" content="2023-01-20T22:00:28+00:00" />
+  <meta name="dc.date" content="2023-01-24" />
+  <meta name="citation_publication_date" content="2023-01-24" />
+  <meta property="article:published_time" content="2023-01-24" />
+  <meta name="dc.modified" content="2023-01-24T02:17:08+00:00" />
+  <meta property="article:modified_time" content="2023-01-24T02:17:08+00:00" />
   <meta name="dc.language" content="en-US" />
   <meta name="citation_language" content="en-US" />
   <meta name="dc.relation.ispartof" content="Manubot" />
@@ -297,13 +297,13 @@ header-includes: |
   <meta name="citation_fulltext_html_url" content="https://greenelab.github.io/covid19-review/" />
   <meta name="citation_pdf_url" content="https://greenelab.github.io/covid19-review/manuscript.pdf" />
   <link rel="alternate" type="application/pdf" href="https://greenelab.github.io/covid19-review/manuscript.pdf" />
-  <link rel="alternate" type="text/html" href="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/" />
-  <meta name="manubot_html_url_versioned" content="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/" />
-  <meta name="manubot_pdf_url_versioned" content="https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf" />
+  <link rel="alternate" type="text/html" href="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/" />
+  <meta name="manubot_html_url_versioned" content="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/" />
+  <meta name="manubot_pdf_url_versioned" content="https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf" />
   <meta property="og:type" content="article" />
   <meta property="twitter:card" content="summary_large_image" />
-  <meta property="og:image" content="https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png" />
-  <meta property="twitter:image" content="https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png" />
+  <meta property="og:image" content="https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png" />
+  <meta property="twitter:image" content="https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png" />
   <link rel="icon" type="image/png" sizes="192x192" href="https://manubot.org/favicon-192x192.png" />
   <link rel="mask-icon" href="https://manubot.org/safari-pinned-tab.svg" color="#ad1457" />
   <meta name="theme-color" content="#ad1457" />
@@ -325,11 +325,11 @@ manubot-clear-requests-cache: false
 
 <small><em>
 This manuscript
-([permalink](https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/))
+([permalink](https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/))
 was automatically generated
-from [greenelab/covid19-review@e166773](https://github.com/greenelab/covid19-review/tree/e1667739727de0e773dd80c8214fa4d6d6112cbd)
-on January 20, 2023.
-It is also available as a [PDF](https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf).
+from [greenelab/covid19-review@3668a38](https://github.com/greenelab/covid19-review/tree/3668a38bb18729aea9d5298d870da0046319e291)
+on January 24, 2023.
+It is also available as a [PDF](https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf).
 Snapshots of individual sections have been published [@individual-pathogenesis; @individual-nutraceuticals; @individual-pharmaceuticals; @individual-methods] or posted as preprints [@individual-diagnostics; @individual-vaccines-traditional; @individual-vaccines-novel].
 </em></small>
 
@@ -2533,14 +2533,14 @@ The scale of the COVID-19 pandemic has made the repurposing and development of p
 
 ![
 **Cumulative global incidence of COVID-19 and SARS.**
-As of January 18, 2023, 667,918,207 COVID-19 cases and 6,729,898 COVID-19 deaths had been reported worldwide since January 22, 2020.
+As of January 22, 2023, 668,835,703 COVID-19 cases and 6,738,594 COVID-19 deaths had been reported worldwide since January 22, 2020.
 A total of 8,432 cases and 813 deaths were reported for SARS from March 17 to July 11, 2003.
 SARS-CoV-1 was officially contained on July 5, 2003, within 9 months of its appearance [@doi:10.3390/ijerph17113973].
 In contrast, SARS-CoV-2 remains a significant global threat nearly two years after its emergence.
 COVID-19 data are from the COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University [@https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series; @doi:10/ggnsjk].
 SARS data are from the WHO [@url:https://www.who.int/health-topics/severe-acute-respiratory-syndrome] and were obtained from a dataset on GitHub [@url:https://github.com/imdevskp/sars-2003-outbreak-data-webscraping-code].
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/csse/csse-deaths.png "Global incidence of COVID-19 and SARS"){#fig:csse-deaths secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/csse/csse-deaths.png "Global incidence of COVID-19 and SARS"){#fig:csse-deaths secno=1}
 
 At first, SARS-CoV-2's rapid shift from an unknown virus to a significant worldwide threat closely paralleled the emergence of _Severe acute respiratory syndrome-related coronavirus_ (SARS-CoV-1), which was responsible for the 2002-03 SARS epidemic.
 The first documented case of COVID-19 was reported in Wuhan, China in November 2019, and the disease quickly spread worldwide in the early months of 2020.
@@ -2597,7 +2597,7 @@ Recruitment status and trial phase are shown only for interventional trials in w
 Common interventions refers to interventions used in at least ten trials.
 Combinations of interventions, such as hydroxychloroquine with azithromycin, are tallied separately from the individual interventions.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-trials.png "COVID-19 clinical trials"){#fig:ebm-trials secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-trials.png "COVID-19 clinical trials"){#fig:ebm-trials secno=1}
 
 The purpose of this review is to provide an evolving resource tracking the status of efforts to repurpose and develop drugs for the treatment of COVID-19.
 We highlight four strategies that provide different paradigms for the identification of potential pharmaceutical treatments.
@@ -3669,7 +3669,7 @@ Therefore, these vaccine platforms, though less novel from a biotechnological st
 
 ### Importance
 
-As of January 18, 2023, there have been over 667,918,207 SARS-CoV-2 cases, and the virus has taken the lives of at least 6,729,898 people globally [@doi:10/ggnsjk].
+As of January 22, 2023, there have been over 668,835,703 SARS-CoV-2 cases, and the virus has taken the lives of at least 6,738,594 people globally [@doi:10/ggnsjk].
 The development, production, and distribution of vaccines is imperative to saving lives, preventing illness, and reducing the economic and social burdens caused by the COVID-19 pandemic.
 Vaccines that use cutting-edge biotechnology have played an important role in mitigating the effects of SARS-CoV-2.
 However, more traditional methods of vaccine development that were refined throughout the twentieth century have been especially critical to increasing vaccine access worldwide.
@@ -3692,7 +3692,7 @@ We review vaccine technologies used for SARS-CoV-2 in two parts: here, the appli
 
 Understanding vaccine development programs that are using well-established technologies is important for a global perspective on COVID-19.
 As of December 2, 2022, 50 SARS-CoV-2 vaccines have been approved for use in at least one country [@url:https://covid19.trackvaccines.org].
-A resource tracking the distribution of 28 vaccines indicates that, as of January 18, 2023, 13.0 billion doses have been administered across 223 countries [@doi:10.1038/s41562-021-01122-8].
+A resource tracking the distribution of 28 vaccines indicates that, as of January 22, 2023, 13.0 billion doses have been administered across 223 countries [@doi:10.1038/s41562-021-01122-8].
 Many of these vaccines use platforms that do not require information about the viral genome, with 20 developed using subunit and 11 using whole-virus approaches [@url:https://covid19.trackvaccines.org].
 The types of vaccines available varies widely throughout the world, as the process of developing and deploying a vaccine is complex and often requires coordination between government, industry, academia, and philanthropic entities [@doi:10.1126/science.abc5312].
 
@@ -3871,7 +3871,7 @@ Table: Inactivated whole-virus vaccines approved in at least one country [@url:h
 | VLA2001                  | Valneva                                                   |
 
 Several whole-virus vaccines have been developed against COVID-19 and are available in countries around the world (Table @tbl:approved-whole-virus).
-As of January 18, 2023, 10 vaccines developed with IWV technology are being distributed in 118 countries (Figure @fig:iwv-distrib).
+As of January 22, 2023, 10 vaccines developed with IWV technology are being distributed in 118 countries (Figure @fig:iwv-distrib).
 Evidence about the value of these vaccines to combat SARS-CoV-2 is available not only from clinical trials, but also from their roll-out following approval.
 Here, a major consideration has been that vaccines often lose efficacy as mutations accumulate in the epitopes of the circulating virus; IWV vaccines may be particularly affected in such cases [@doi:10.3389/fimmu.2019.00594].
 This loss of specificity over time is likely to be influenced by the evolution of the virus, and specifically by the rate of evolution in the region of the genome that codes for the antigenic spike protein.
@@ -3879,11 +3879,11 @@ Here we review three vaccine development programs and their successes in a real-
 
 ![
 **Worldwide availability of vaccines developed using inactivated whole viruses.**
-This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data [@url:https://ourworldindata.org/coronavirus] and plotted using geopandas [@doi:10.5281/zenodo.5573592].
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/inactivated.png "Availability of inactivated whole virus vaccines"){#fig:iwv-distrib secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/inactivated.png "Availability of inactivated whole virus vaccines"){#fig:iwv-distrib secno=1}
 
 ##### Sinovac's CoronaVac
 
@@ -3980,7 +3980,7 @@ A detailed preprint describing the double-blind, randomized, controlled phase II
 Based on a final enrollment of 25,798 people (~1:1 vaccine:placebo), overall VE against symptomatic COVID-19 was estimated at 77.8% and against severe disease and asymptomatic infection was reported as 93.4% and 63.6%, respectively [@doi:10/gnkdnx].
 The vaccine was also reported to be well tolerated, with fewer severe events occurring in the Covaxin group (0.3%) than in the placebo group (0.5%) [@doi:10/gnkdnx].
 One case of a serious AE potentially related to the vaccine, immune thrombocytopenic purpura, was reported, although this patient was seropositive for SARS-CoV-2 at the baseline observation point [@doi:10/gnkdnx].
-As of January 19, 2023, Covaxin was approved for emergency use in 31 countries across Africa, Asia, Europe, and South America, including Guyana, India, Iran, Zimbabwe, Nepal, Mauritius, Mexico, Nepal, Paraguay, and the Philippines [@url:https://covid19.trackvaccines.org/vaccines/9].
+As of January 23, 2023, Covaxin was approved for emergency use in 31 countries across Africa, Asia, Europe, and South America, including Guyana, India, Iran, Zimbabwe, Nepal, Mauritius, Mexico, Nepal, Paraguay, and the Philippines [@url:https://covid19.trackvaccines.org/vaccines/9].
 
 Like with all vaccines, the continued evolution of SARS-CoV-2 poses a challenge to the effectiveness of Covaxin.
 In this case, the phase III clinical trial did evaluate the efficacy of Covaxin in response to variants circulating in mid-to-late 2020 [@doi:10/gnkdnx].
@@ -4087,27 +4087,27 @@ Table: Subunit vaccines approved for use in at least one country [@url:https://c
 
 The development of subunit vaccines against SARS-CoV-2 is a remarkable achievement given the short period of time since the emergence of SARS-CoV-2 in late 2019, particularly considering these types of vaccines have not played a major role in previous pandemics compared to LAV and IWV vaccines.
 More than 20 protein subunit vaccines from companies such as Sanofi/GlaxoSmithKline, Nanogen, and the Serum Institute of India have entered clinical trials for COVID-19 since the beginning of the pandemic [@url:https://covid19.trackvaccines.org/vaccines], 20 have been approved, and at least 9 are being administered worldwide [@doi:10.1038/s41562-021-01122-8; @url:https://covid19.trackvaccines.org] (Table @tbl:approved-subunit).
-As of January 18, 2023, protein subunit vaccines are being distributed in at least 42 countries (Figure @fig:ps-distrib).
+As of January 22, 2023, protein subunit vaccines are being distributed in at least 42 countries (Figure @fig:ps-distrib).
 
 ![
 **Worldwide availability of vaccines developed using protein subunit.**
-This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data [@url:https://ourworldindata.org/coronavirus; @doi:10.1038/s41562-021-01122-8] and plotted using geopandas [@doi:10.5281/zenodo.5573592].
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/protein_subunit.png "Availability of protein subunit vaccines"){#fig:ps-distrib secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/protein_subunit.png "Availability of protein subunit vaccines"){#fig:ps-distrib secno=1}
 
 VLP vaccines have not progressed as rapidly.
 Programs seeking to develop VLP vaccines have used either the full-length S protein or the RBD of the S protein specifically as an antigen, although some use several different SARS-CoV-2 proteins [@doi:10.1016/j.addr.2021.01.001].
-As of January 18, 2023, only one VLP was available in one country (Canada) [@doi:10.1038/s41562-021-01122-8].<!--Canada/Covifenz info is hardcoded-->
+As of January 22, 2023, only one VLP was available in one country (Canada) [@doi:10.1038/s41562-021-01122-8].<!--Canada/Covifenz info is hardcoded-->
 
 ![
 **Worldwide availability of vaccines developed with VLPs.**
-This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on VLP technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data [@url:https://ourworldindata.org/coronavirus] and plotted using geopandas [@doi:10.5281/zenodo.5573592].
 The color scale is based on the number of vaccines of this type included in the OWID dataset as a whole, not the maximum observed in a single country.
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/VLP.png "Availability of protein subunit vaccines"){#fig:vlp-distrib secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/VLP.png "Availability of protein subunit vaccines"){#fig:vlp-distrib secno=1}
 
 #### Novavax's Nuvaxovid
 
@@ -4264,8 +4264,8 @@ Coupled with the reduced barriers to development and transportation relative to
 The unprecedented deployment of COVID-19 vaccines in under a year from the identification of SARS-CoV-2 led to a new challenge: the formation of rapid global vaccine production and distribution plans.
 The development of vaccines is costly and complicated, but vaccine distribution can be just as challenging.
 Logistical considerations such as transport, storage, equipment (e.g., syringes), the workforce to administer the vaccines, and a continual supply from the manufacturers to meet global demands all must be accounted for and vary globally due to economic, geographic, and sociopolitical reasons [@doi:10.1016/j.eclinm.2020.100674; @doi:10.1126/science.abe2803; @doi:10.1126/sciadv.abf1374].
-As of January 12, 2023, at least 13.0 billion vaccine doses had been administered in at least 223 countries worldwide using 28 different vaccines [@url:https://ourworldindata.org/coronavirus].>
-The daily global vaccination rate at this time was 260.0 per million.
+As of January 16, 2023, at least 13.0 billion vaccine doses had been administered in at least 223 countries worldwide using 28 different vaccines [@url:https://ourworldindata.org/coronavirus].>
+The daily global vaccination rate at this time was 251.0 per million.
 
 However, the distribution of these doses is not uniform around the globe.
 Latin America leads world vaccination rates with at least 82% of individuals in this region receiving one vaccine dose followed by the U.S. and Canada (81%), Asia-Pacific (81%), Europe (70%), the Middle East (58%), and Africa with only 33% as of November 2022 [@url:https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html].
@@ -4286,13 +4286,13 @@ Therefore, vaccine development programs that utilized established vaccine techno
 
 ![
 **Vaccine Distribution across Platform Types as a Function of GDP.**
-The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 18, 2023, by platform type, is shown as a function of GDP.
+The total number of doses of the original formulation of each vaccine that were distributed within each country as of January 22, 2023, by platform type, is shown as a function of GDP.
 These data are retrieved from Our World in Data [@url:https://ourworldindata.org/coronavirus; @doi:10.1038/s41562-021-01122-8] and plotted using the Python package plotnine [@url:https://github.com/has2k1/plotnine].
 Lines show a general trend in the data and are drawn using geom_smooth [@url:https://ggplot2.tidyverse.org/reference/geom_smooth.html].
 The list of countries included in the dataset is available from OWID [@url:https://github.com/owid/covid-19-data/blob/master/public/data/vaccinations/locations.csv].
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
 Axes are not scaled per capita because both variables are modulated by population size.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/OWID_doseTypebyGDP.png "Distribution of vaccines according to GDP"){#fig:gdpscatter secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/OWID_doseTypebyGDP.png "Distribution of vaccines according to GDP"){#fig:gdpscatter secno=1}
 
 <!-- Figure is not rendering -->
 
@@ -4830,11 +4830,11 @@ The second reported promising results from a phase I trial that administered the
 
 ![
 **Worldwide availability of vaccines developed using non-replicating viral vectors.**<!--As a general comment on the choropleths, is there any way to increase resolution. Hard to see what’s happening in Europe and south east Asia.--><!--Updated from 300 to 600 after this comment in #1169, let's see if it helped-->
-This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines using non-replicating viral vectors that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data [@doi:10.1038/s41562-021-01122-8] and plotted using geopandas [@doi:10.5281/zenodo.5573592].
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
 Note that this figure draws from a different data source than Table @tbl:approved-DNA and does not necessarily include data for every vaccine developed within this category.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/non_replicating_viral_vector.png "Availability of non-replicating viral-vectored vaccines"){#fig:nrvv-distrib secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/non_replicating_viral_vector.png "Availability of non-replicating viral-vectored vaccines"){#fig:nrvv-distrib secno=1}
 
 While not all of the above results were available at the time that vaccine development programs against SARS-CoV-2 began, at least three viral vector vaccines have also been developed against SARS-CoV-2 (Figure @fig:nrvv-distrib).
 First, a collaboration between AstraZeneca and researchers at the University of Oxford successfully applied a viral vector approach to the development of a vaccine against SARS-CoV-2 using the replication-deficient ChAdOx1 vector modified to encode the S protein of SARS-CoV-2 [@doi:10.1038/s41586-020-2608-y].
@@ -4856,7 +4856,7 @@ The JNJ-78436735 candidate was selected for its favorable immunogenicity profile
 The one- versus two-dose regimen was then tested in volunteers through a phase I/IIa trial [@doi:10.1056/NEJMoa2034201; @doi:10.1056/NEJMoa2117608].
 A major difference between this vaccine and the other two in this category is that the S protein immunogen is stabilized in its prefusion conformation, while in the Sputnik V and AstraZeneca vaccines it is not.
 
-As of January 18, 2023, data describing the distribution of 5 viral-vectored vaccines in 202 countries are available (Figure @fig:nrvv-distrib).
+As of January 22, 2023, data describing the distribution of 5 viral-vectored vaccines in 202 countries are available (Figure @fig:nrvv-distrib).
 ChAdOx1 nCoV-19 was first approved for emergency use on December 30, 2020 in the U.K. [@url:https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html].
 Sputnik V was available soon after, and early as January 2021, Sputnik V had been administered to 1.5 million Russians [@url:https://www.brusselstimes.com/news-contents/world/149039/1-5-million-people-have-received-sputnik-v-vaccine-russia-says-russian-direct-investment-fund-mikhail-murashko] and began distributing doses to other countries within Europe such as Belarus, Bosnia-Herzegovina, Hungary, San Marino, Serbia, and Slovakia [@url:https://www.euronews.com/2021/02/12/hungary-to-begin-using-russia-s-sputnik-v-vaccine-today; @url:https://www.euronews.com/2021/02/24/san-marino-buys-russia-s-sputnik-v-after-eu-vaccine-delivery-delays; @url:https://www.themoscowtimes.com/2020/12/29/belarus-starts-coronavirus-vaccination-with-sputnik-v-a72512].
 
@@ -4983,15 +4983,15 @@ Both require two doses approximately one month apart.
 The first was Pfizer/BioNTech's BNT162b2, which contains the full prefusion stabilized, membrane-anchored SARS-CoV-2 Spike protein in a vaccine formulation based on modified mRNA (modRNA) technology [@doi:10.1101/cshperspect.a014035; @url:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0].
 The second mRNA vaccine, mRNA-1273 developed by ModernaTX, is comprised by a conventional LNP-encapsulated RNA encoding a full-length prefusion stabilized S protein for SARS-CoV-2 [@clinicaltrials:NCT04283461].
 The vaccine candidates developed against SARS-CoV-2 using mRNA vectors utilize similar principles and technologies, although there are slight differences in implementation among candidates such as the formulation of the platform and the specific components of the Spike protein encapsulated (e.g., the full Spike protein vs. the RBD alone) [@doi:10.3389/fphar.2020.00937].
-As of January 18, 2023, 2 mRNA vaccines are available in 169 countries (Figure @fig:mRNA-distrib).
+As of January 22, 2023, 2 mRNA vaccines are available in 169 countries (Figure @fig:mRNA-distrib).
 
 ![
 **Worldwide availability of vaccines developed using mRNA.**
-This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 18, 2023.
+This figure reflects the number of vaccines based on mRNA technology that were available in each country as of January 22, 2023.
 These data are retrieved from Our World in Data [@doi:10.1038/s41562-021-01122-8] and plotted using geopandas [@doi:10.5281/zenodo.5573592].
 See https://greenelab.github.io/covid19-review/ for the most recent version of this figure, which is updated daily.
 Note that this figure draws from a different data source than Table @tbl:approved-RNA and does not necessarily include data for every vaccine developed within this category.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/RNA.png "Availability of mRNA vaccines"){#fig:mRNA-distrib secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/RNA.png "Availability of mRNA vaccines"){#fig:mRNA-distrib secno=1}
 
 The rapid and simultaneous development of these vaccines was met with some controversy related to intellectual property (IP).
 First, the National Institutes of Health (NIH) and Moderna became involved in a patent dispute, after researchers at the NIH argued they were unfairly excluded from some patents filed based on their IP after they generated the stabilized modRNA sequence used in the vaccine [@doi:10.1038/d41586-021-03535-x].
@@ -6057,7 +6057,7 @@ Trials that recruit across multiple countries do appear to broaden geographic re
 The density of clinical trials is reported at the country level.
 As of December 31, 2020, there are 6,987 trials in the University of Oxford Evidence-Based Medicine Data Lab's COVID-19 TrialsTracker [@doi:10.5281/zenodo.3732709], of which 3,962 are interventional.
 The top figure demonstrates the density of interventional trials recruiting only from a singular country, while the bottom shows the distribution of recruitment for interventional trials that involve more than one country.
-](https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-map.png "COVID-19 clinical trials"){#fig:ebm-map secno=1}
+](https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-map.png "COVID-19 clinical trials"){#fig:ebm-map secno=1}
 
 A few different concerns arise from this skewed geographic representation in clinical trial recruitment.
 First, treatments such as remdesivir that are promising but primarily available to clinical trial participants are unlikely to be accessible by people in many countries.
diff --git a/manuscript.pdf b/manuscript.pdf
index b61cb8f26..e92151b9f 100644
Binary files a/manuscript.pdf and b/manuscript.pdf differ
diff --git a/references.json b/references.json
index bc6ecefa1..63db2a732 100644
--- a/references.json
+++ b/references.json
@@ -2818,7 +2818,7 @@
         [
           "2023",
           1,
-          19
+          22
         ]
       ]
     },
@@ -158568,7 +158568,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -159103,7 +159103,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -159119,7 +159119,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -159291,7 +159291,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -159320,7 +159320,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -160123,7 +160123,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -160255,7 +160255,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -160289,7 +160289,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -161243,7 +161243,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -161531,7 +161531,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -161565,7 +161565,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -162068,7 +162068,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -162102,7 +162102,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -162710,7 +162710,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -162735,7 +162735,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -162760,7 +162760,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -164094,7 +164094,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -164754,7 +164754,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -164946,7 +164946,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -166352,7 +166352,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -166724,7 +166724,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -166796,7 +166796,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -166836,7 +166836,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167058,7 +167058,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167298,7 +167298,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167634,7 +167634,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167697,7 +167697,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167733,7 +167733,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
@@ -167812,7 +167812,7 @@
         [
           "2023",
           1,
-          20
+          23
         ]
       ]
     },
diff --git a/vaccines-novel-manuscript.docx b/vaccines-novel-manuscript.docx
new file mode 100644
index 000000000..7d1380ccb
Binary files /dev/null and b/vaccines-novel-manuscript.docx differ
diff --git a/vaccines-trad-manuscript.docx b/vaccines-trad-manuscript.docx
index 1c3e707ad..30310a390 100644
Binary files a/vaccines-trad-manuscript.docx and b/vaccines-trad-manuscript.docx differ
diff --git a/variables.json b/variables.json
index 03064c6f5..a4efd766b 100644
--- a/variables.json
+++ b/variables.json
@@ -8,7 +8,7 @@
       "viral infection"
     ],
     "lang": "en-US",
-    "date-meta": "2023-01-20",
+    "date-meta": "2023-01-24",
     "author-meta": [
       "Halie M. Rando",
       "Casey S. Greene",
@@ -65,7 +65,7 @@
       "Jesse G. Meyer",
       "Ariel I. Mundo"
     ],
-    "header-includes": "<!--\nManubot generated metadata rendered from header-includes-template.html.\nSuggest improvements at https://github.com/manubot/manubot/blob/main/manubot/process/header-includes-template.html\n-->\n<meta name=\"dc.format\" content=\"text/html\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta name=\"dc.title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"citation_title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"og:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"twitter:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"dc.date\" content=\"2023-01-20\" />\n<meta name=\"citation_publication_date\" content=\"2023-01-20\" />\n<meta property=\"article:published_time\" content=\"2023-01-20\" />\n<meta name=\"dc.modified\" content=\"2023-01-20T22:00:28+00:00\" />\n<meta property=\"article:modified_time\" content=\"2023-01-20T22:00:28+00:00\" />\n<meta name=\"dc.language\" content=\"en-US\" />\n<meta name=\"citation_language\" content=\"en-US\" />\n<meta name=\"dc.relation.ispartof\" content=\"Manubot\" />\n<meta name=\"dc.publisher\" content=\"Manubot\" />\n<meta name=\"citation_journal_title\" content=\"Manubot\" />\n<meta name=\"citation_technical_report_institution\" content=\"Manubot\" />\n<meta name=\"citation_author\" content=\"Halie M. Rando\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Informatics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7688-1770\" />\n<meta name=\"twitter:creator\" content=\"@tamefoxtime\" />\n<meta name=\"citation_author\" content=\"Casey S. Greene\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Childhood Cancer Data Lab, Alex&#39;s Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Informatics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8713-9213\" />\n<meta name=\"twitter:creator\" content=\"@GreeneScientist\" />\n<meta name=\"citation_author\" content=\"Michael P. Robson\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4859-0033\" />\n<meta name=\"citation_author\" content=\"Simina M. Boca\" />\n<meta name=\"citation_author_institution\" content=\"Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1400-3398\" />\n<meta name=\"citation_author\" content=\"Nils Wellhausen\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8955-7582\" />\n<meta name=\"citation_author\" content=\"Ronan Lordan\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-9668-3368\" />\n<meta name=\"twitter:creator\" content=\"@el_ronan\" />\n<meta name=\"citation_author\" content=\"Christian Brueffer\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Sciences, Lund University, Lund, Sweden\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3826-0989\" />\n<meta name=\"twitter:creator\" content=\"@cbrueffer\" />\n<meta name=\"citation_author\" content=\"Sandipan Ray\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, Telangana, India\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9960-5768\" />\n<meta name=\"citation_author\" content=\"Lucy D\\&#39;Agostino McGowan\" />\n<meta name=\"citation_author_institution\" content=\"Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7297-9359\" />\n<meta name=\"twitter:creator\" content=\"@LucyStats\" />\n<meta name=\"citation_author\" content=\"Anthony Gitter\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Morgridge Institute for Research, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5324-9833\" />\n<meta name=\"twitter:creator\" content=\"@anthonygitter\" />\n<meta name=\"citation_author\" content=\"Anna Ada Dattoli\" />\n<meta name=\"citation_author_institution\" content=\"Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology &amp; Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1462-831X\" />\n<meta name=\"twitter:creator\" content=\"@aadattoli\" />\n<meta name=\"citation_author\" content=\"Ryan Velazquez\" />\n<meta name=\"citation_author_institution\" content=\"Azimuth1, McLean, Virginia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3655-3403\" />\n<meta name=\"citation_author\" content=\"John P. Barton\" />\n<meta name=\"citation_author_institution\" content=\"Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1467-421X\" />\n<meta name=\"twitter:creator\" content=\"@_jpbarton\" />\n<meta name=\"citation_author\" content=\"Jeffrey M. Field\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7161-7284\" />\n<meta name=\"citation_author\" content=\"Bharath Ramsundar\" />\n<meta name=\"citation_author_institution\" content=\"The DeepChem Project, https://deepchem.io/\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8450-4262\" />\n<meta name=\"twitter:creator\" content=\"@rbhar90\" />\n<meta name=\"citation_author\" content=\"Adam L. MacLean\" />\n<meta name=\"citation_author_institution\" content=\"Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0689-7907\" />\n<meta name=\"twitter:creator\" content=\"@adamlmaclean\" />\n<meta name=\"citation_author\" content=\"Alexandra J. Lee\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0208-3730\" />\n<meta name=\"citation_author\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author_institution\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author\" content=\"Fengling Hu\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1081-5038\" />\n<meta name=\"twitter:creator\" content=\"@hufengling\" />\n<meta name=\"citation_author\" content=\"Nafisa M. Jadavji\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Science, Midwestern University, Glendale, AZ, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3557-7307\" />\n<meta name=\"twitter:creator\" content=\"@nafisajadavji\" />\n<meta name=\"citation_author\" content=\"Elizabeth Sell\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9658-1107\" />\n<meta name=\"citation_author\" content=\"Vincent Rubinetti\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4655-3773\" />\n<meta name=\"citation_author\" content=\"Jinhui Wang\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-8130\" />\n<meta name=\"citation_author\" content=\"Diane N. Rafizadeh\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2838-067X\" />\n<meta name=\"citation_author\" content=\"Ashwin N. Skelly\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1565-3376\" />\n<meta name=\"citation_author\" content=\"Marouen Ben Guebila\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-5934-966X\" />\n<meta name=\"twitter:creator\" content=\"@marouenbg\" />\n<meta name=\"citation_author\" content=\"Likhitha Kolla\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1169-906X\" />\n<meta name=\"twitter:creator\" content=\"@lkolla2018\" />\n<meta name=\"citation_author\" content=\"David Manheim\" />\n<meta name=\"citation_author_institution\" content=\"1DaySooner, Delaware, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Risk and Health Communication Research Center, School of Public Health, University of Haifa, Haifa, Israel\" />\n<meta name=\"citation_author_institution\" content=\"Technion, Israel Institute of Technology, Haifa, Israel\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8599-8380\" />\n<meta name=\"twitter:creator\" content=\"@davidmanheim\" />\n<meta name=\"citation_author\" content=\"Soumita Ghosh\" />\n<meta name=\"citation_author_institution\" content=\"Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2783-2750\" />\n<meta name=\"citation_author\" content=\"James Brian Byrd\" />\n<meta name=\"citation_author_institution\" content=\"University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0509-3520\" />\n<meta name=\"twitter:creator\" content=\"@thebyrdlab\" />\n<meta name=\"citation_author\" content=\"YoSon Park\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0465-4744\" />\n<meta name=\"twitter:creator\" content=\"@__yoson__\" />\n<meta name=\"citation_author\" content=\"Vikas Bansal\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Data Science and Machine Learning Group, German Center for Neurodegenerative Diseases, Tübingen 72076, Germany\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0944-7226\" />\n<meta name=\"twitter:creator\" content=\"@VikasBansal1989\" />\n<meta name=\"citation_author\" content=\"Stephen Capone\" />\n<meta name=\"citation_author_institution\" content=\"St. George&#39;s University School of Medicine, St. George&#39;s, Grenada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7231-1535\" />\n<meta name=\"citation_author\" content=\"John J. Dziak\" />\n<meta name=\"citation_author_institution\" content=\"Edna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0762-5495\" />\n<meta name=\"citation_author\" content=\"Yuchen Sun\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author\" content=\"Yanjun Qi\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-7453\" />\n<meta name=\"citation_author\" content=\"Lamonica Shinholster\" />\n<meta name=\"citation_author_institution\" content=\"Mercer University, Macon, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-6285-005X\" />\n<meta name=\"citation_author\" content=\"Temitayo Lukan\" />\n<meta name=\"citation_author_institution\" content=\"University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author\" content=\"Sergey Knyazev\" />\n<meta name=\"citation_author_institution\" content=\"Georgia State University, Atlanta, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0385-1831\" />\n<meta name=\"twitter:creator\" content=\"@SeKnyaz\" />\n<meta name=\"citation_author\" content=\"Dimitri Perrin\" />\n<meta name=\"citation_author_institution\" content=\"School of Computer Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_institution\" content=\"Centre for Data Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4007-5256\" />\n<meta name=\"twitter:creator\" content=\"@dperrin\" />\n<meta name=\"citation_author\" content=\"Serghei Mangul\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-4770-3443\" />\n<meta name=\"twitter:creator\" content=\"@serghei_mangul\" />\n<meta name=\"citation_author\" content=\"Shikta Das\" />\n<meta name=\"citation_author_institution\" content=\"C4X Discovery, London, United Kingdom\" />\n<meta name=\"citation_author_institution\" content=\"Medical Research Council LHA, Institute of Cardiovascular Studies, University College London, London, United Kingdom\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-8291-2788\" />\n<meta name=\"twitter:creator\" content=\"@shikta_das\" />\n<meta name=\"citation_author\" content=\"Gregory L Szeto\" />\n<meta name=\"citation_author_institution\" content=\"Allen Institute for Immunology, Seattle, WA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7604-1333\" />\n<meta name=\"twitter:creator\" content=\"@greg_szeto\" />\n<meta name=\"citation_author\" content=\"Tiago Lubiana\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-2473-2313\" />\n<meta name=\"twitter:creator\" content=\"@lubianat\" />\n<meta name=\"citation_author\" content=\"David Mai\" />\n<meta name=\"citation_author_institution\" content=\"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_institution\" content=\"Center for Cellular Immunotherapies, Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9238-0164\" />\n<meta name=\"twitter:creator\" content=\"@lococyte\" />\n<meta name=\"citation_author\" content=\"COVID-19 Review Consortium\" />\n<meta name=\"citation_author\" content=\"Rishi Raj Goel\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1715-5191\" />\n<meta name=\"twitter:creator\" content=\"@rishirajgoel\" />\n<meta name=\"citation_author\" content=\"Joel D Boerckel\" />\n<meta name=\"citation_author_institution\" content=\"Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-3126-3025\" />\n<meta name=\"twitter:creator\" content=\"@jboerckel\" />\n<meta name=\"citation_author\" content=\"Amruta Naik\" />\n<meta name=\"citation_author_institution\" content=\"Children&#39;s Hospital of Philadelphia, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0673-2643\" />\n<meta name=\"citation_author\" content=\"Yusha Sun\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-4835-3000\" />\n<meta name=\"citation_author\" content=\"Daniel S. Himmelstein\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Related Sciences\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3012-7446\" />\n<meta name=\"twitter:creator\" content=\"@dhimmel\" />\n<meta name=\"citation_author\" content=\"Jeremy P. Kamil\" />\n<meta name=\"citation_author_institution\" content=\"Department of Microbiology and Immunology, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8422-7656\" />\n<meta name=\"citation_author\" content=\"Jesse G. Meyer\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-2753-3926\" />\n<meta name=\"citation_author\" content=\"Ariel I. Mundo\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Engineering, University of Arkansas, Fayetteville, Arkansas, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-6014-4538\" />\n<link rel=\"canonical\" href=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"og:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"twitter:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_fulltext_html_url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_pdf_url\" content=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"application/pdf\" href=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"text/html\" href=\"https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/\" />\n<meta name=\"manubot_html_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/\" />\n<meta name=\"manubot_pdf_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta property=\"twitter:card\" content=\"summary_large_image\" />\n<meta property=\"og:image\" content=\"https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png\" />\n<meta property=\"twitter:image\" content=\"https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png\" />\n<link rel=\"icon\" type=\"image/png\" sizes=\"192x192\" href=\"https://manubot.org/favicon-192x192.png\" />\n<link rel=\"mask-icon\" href=\"https://manubot.org/safari-pinned-tab.svg\" color=\"#ad1457\" />\n<meta name=\"theme-color\" content=\"#ad1457\" />\n<!-- end Manubot generated metadata -->\n",
+    "header-includes": "<!--\nManubot generated metadata rendered from header-includes-template.html.\nSuggest improvements at https://github.com/manubot/manubot/blob/main/manubot/process/header-includes-template.html\n-->\n<meta name=\"dc.format\" content=\"text/html\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta name=\"dc.title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"citation_title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"og:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta property=\"twitter:title\" content=\"SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics\" />\n<meta name=\"dc.date\" content=\"2023-01-24\" />\n<meta name=\"citation_publication_date\" content=\"2023-01-24\" />\n<meta property=\"article:published_time\" content=\"2023-01-24\" />\n<meta name=\"dc.modified\" content=\"2023-01-24T02:17:08+00:00\" />\n<meta property=\"article:modified_time\" content=\"2023-01-24T02:17:08+00:00\" />\n<meta name=\"dc.language\" content=\"en-US\" />\n<meta name=\"citation_language\" content=\"en-US\" />\n<meta name=\"dc.relation.ispartof\" content=\"Manubot\" />\n<meta name=\"dc.publisher\" content=\"Manubot\" />\n<meta name=\"citation_journal_title\" content=\"Manubot\" />\n<meta name=\"citation_technical_report_institution\" content=\"Manubot\" />\n<meta name=\"citation_author\" content=\"Halie M. Rando\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Informatics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7688-1770\" />\n<meta name=\"twitter:creator\" content=\"@tamefoxtime\" />\n<meta name=\"citation_author\" content=\"Casey S. Greene\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Childhood Cancer Data Lab, Alex&#39;s Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Informatics, University of Colorado Anschutz School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8713-9213\" />\n<meta name=\"twitter:creator\" content=\"@GreeneScientist\" />\n<meta name=\"citation_author\" content=\"Michael P. Robson\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4859-0033\" />\n<meta name=\"citation_author\" content=\"Simina M. Boca\" />\n<meta name=\"citation_author_institution\" content=\"Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1400-3398\" />\n<meta name=\"citation_author\" content=\"Nils Wellhausen\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8955-7582\" />\n<meta name=\"citation_author\" content=\"Ronan Lordan\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-9668-3368\" />\n<meta name=\"twitter:creator\" content=\"@el_ronan\" />\n<meta name=\"citation_author\" content=\"Christian Brueffer\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Sciences, Lund University, Lund, Sweden\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3826-0989\" />\n<meta name=\"twitter:creator\" content=\"@cbrueffer\" />\n<meta name=\"citation_author\" content=\"Sandipan Ray\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy 502285, Telangana, India\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9960-5768\" />\n<meta name=\"citation_author\" content=\"Lucy D\\&#39;Agostino McGowan\" />\n<meta name=\"citation_author_institution\" content=\"Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7297-9359\" />\n<meta name=\"twitter:creator\" content=\"@LucyStats\" />\n<meta name=\"citation_author\" content=\"Anthony Gitter\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Morgridge Institute for Research, Madison, Wisconsin, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5324-9833\" />\n<meta name=\"twitter:creator\" content=\"@anthonygitter\" />\n<meta name=\"citation_author\" content=\"Anna Ada Dattoli\" />\n<meta name=\"citation_author_institution\" content=\"Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology &amp; Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1462-831X\" />\n<meta name=\"twitter:creator\" content=\"@aadattoli\" />\n<meta name=\"citation_author\" content=\"Ryan Velazquez\" />\n<meta name=\"citation_author_institution\" content=\"Azimuth1, McLean, Virginia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3655-3403\" />\n<meta name=\"citation_author\" content=\"John P. Barton\" />\n<meta name=\"citation_author_institution\" content=\"Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1467-421X\" />\n<meta name=\"twitter:creator\" content=\"@_jpbarton\" />\n<meta name=\"citation_author\" content=\"Jeffrey M. Field\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7161-7284\" />\n<meta name=\"citation_author\" content=\"Bharath Ramsundar\" />\n<meta name=\"citation_author_institution\" content=\"The DeepChem Project, https://deepchem.io/\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8450-4262\" />\n<meta name=\"twitter:creator\" content=\"@rbhar90\" />\n<meta name=\"citation_author\" content=\"Adam L. MacLean\" />\n<meta name=\"citation_author_institution\" content=\"Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, California, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0689-7907\" />\n<meta name=\"twitter:creator\" content=\"@adamlmaclean\" />\n<meta name=\"citation_author\" content=\"Alexandra J. Lee\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0208-3730\" />\n<meta name=\"citation_author\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author_institution\" content=\"Immunology Institute of the Icahn School of Medicine\" />\n<meta name=\"citation_author\" content=\"Fengling Hu\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1081-5038\" />\n<meta name=\"twitter:creator\" content=\"@hufengling\" />\n<meta name=\"citation_author\" content=\"Nafisa M. Jadavji\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Science, Midwestern University, Glendale, AZ, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3557-7307\" />\n<meta name=\"twitter:creator\" content=\"@nafisajadavji\" />\n<meta name=\"citation_author\" content=\"Elizabeth Sell\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9658-1107\" />\n<meta name=\"citation_author\" content=\"Vincent Rubinetti\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4655-3773\" />\n<meta name=\"citation_author\" content=\"Jinhui Wang\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-8130\" />\n<meta name=\"citation_author\" content=\"Diane N. Rafizadeh\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2838-067X\" />\n<meta name=\"citation_author\" content=\"Ashwin N. Skelly\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1565-3376\" />\n<meta name=\"citation_author\" content=\"Marouen Ben Guebila\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-5934-966X\" />\n<meta name=\"twitter:creator\" content=\"@marouenbg\" />\n<meta name=\"citation_author\" content=\"Likhitha Kolla\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-1169-906X\" />\n<meta name=\"twitter:creator\" content=\"@lkolla2018\" />\n<meta name=\"citation_author\" content=\"David Manheim\" />\n<meta name=\"citation_author_institution\" content=\"1DaySooner, Delaware, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Risk and Health Communication Research Center, School of Public Health, University of Haifa, Haifa, Israel\" />\n<meta name=\"citation_author_institution\" content=\"Technion, Israel Institute of Technology, Haifa, Israel\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8599-8380\" />\n<meta name=\"twitter:creator\" content=\"@davidmanheim\" />\n<meta name=\"citation_author\" content=\"Soumita Ghosh\" />\n<meta name=\"citation_author_institution\" content=\"Institute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-2783-2750\" />\n<meta name=\"citation_author\" content=\"James Brian Byrd\" />\n<meta name=\"citation_author_institution\" content=\"University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0509-3520\" />\n<meta name=\"twitter:creator\" content=\"@thebyrdlab\" />\n<meta name=\"citation_author\" content=\"YoSon Park\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0465-4744\" />\n<meta name=\"twitter:creator\" content=\"@__yoson__\" />\n<meta name=\"citation_author\" content=\"Vikas Bansal\" />\n<meta name=\"citation_author_institution\" content=\"Biomedical Data Science and Machine Learning Group, German Center for Neurodegenerative Diseases, Tübingen 72076, Germany\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-0944-7226\" />\n<meta name=\"twitter:creator\" content=\"@VikasBansal1989\" />\n<meta name=\"citation_author\" content=\"Stephen Capone\" />\n<meta name=\"citation_author_institution\" content=\"St. George&#39;s University School of Medicine, St. George&#39;s, Grenada\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7231-1535\" />\n<meta name=\"citation_author\" content=\"John J. Dziak\" />\n<meta name=\"citation_author_institution\" content=\"Edna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0762-5495\" />\n<meta name=\"citation_author\" content=\"Yuchen Sun\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author\" content=\"Yanjun Qi\" />\n<meta name=\"citation_author_institution\" content=\"Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-5796-7453\" />\n<meta name=\"citation_author\" content=\"Lamonica Shinholster\" />\n<meta name=\"citation_author_institution\" content=\"Mercer University, Macon, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-6285-005X\" />\n<meta name=\"citation_author\" content=\"Temitayo Lukan\" />\n<meta name=\"citation_author_institution\" content=\"University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author\" content=\"Sergey Knyazev\" />\n<meta name=\"citation_author_institution\" content=\"Georgia State University, Atlanta, GA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0385-1831\" />\n<meta name=\"twitter:creator\" content=\"@SeKnyaz\" />\n<meta name=\"citation_author\" content=\"Dimitri Perrin\" />\n<meta name=\"citation_author_institution\" content=\"School of Computer Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_institution\" content=\"Centre for Data Science, Queensland University of Technology, Brisbane, Australia\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-4007-5256\" />\n<meta name=\"twitter:creator\" content=\"@dperrin\" />\n<meta name=\"citation_author\" content=\"Serghei Mangul\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-4770-3443\" />\n<meta name=\"twitter:creator\" content=\"@serghei_mangul\" />\n<meta name=\"citation_author\" content=\"Shikta Das\" />\n<meta name=\"citation_author_institution\" content=\"C4X Discovery, London, United Kingdom\" />\n<meta name=\"citation_author_institution\" content=\"Medical Research Council LHA, Institute of Cardiovascular Studies, University College London, London, United Kingdom\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-8291-2788\" />\n<meta name=\"twitter:creator\" content=\"@shikta_das\" />\n<meta name=\"citation_author\" content=\"Gregory L Szeto\" />\n<meta name=\"citation_author_institution\" content=\"Allen Institute for Immunology, Seattle, WA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-7604-1333\" />\n<meta name=\"twitter:creator\" content=\"@greg_szeto\" />\n<meta name=\"citation_author\" content=\"Tiago Lubiana\" />\n<meta name=\"citation_author_institution\" content=\"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-2473-2313\" />\n<meta name=\"twitter:creator\" content=\"@lubianat\" />\n<meta name=\"citation_author\" content=\"David Mai\" />\n<meta name=\"citation_author_institution\" content=\"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_institution\" content=\"Center for Cellular Immunotherapies, Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-9238-0164\" />\n<meta name=\"twitter:creator\" content=\"@lococyte\" />\n<meta name=\"citation_author\" content=\"COVID-19 Review Consortium\" />\n<meta name=\"citation_author\" content=\"Rishi Raj Goel\" />\n<meta name=\"citation_author_institution\" content=\"Institute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-1715-5191\" />\n<meta name=\"twitter:creator\" content=\"@rishirajgoel\" />\n<meta name=\"citation_author\" content=\"Joel D Boerckel\" />\n<meta name=\"citation_author_institution\" content=\"Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-3126-3025\" />\n<meta name=\"twitter:creator\" content=\"@jboerckel\" />\n<meta name=\"citation_author\" content=\"Amruta Naik\" />\n<meta name=\"citation_author_institution\" content=\"Children&#39;s Hospital of Philadelphia, Philadelphia, PA, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-0673-2643\" />\n<meta name=\"citation_author\" content=\"Yusha Sun\" />\n<meta name=\"citation_author_institution\" content=\"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-4835-3000\" />\n<meta name=\"citation_author\" content=\"Daniel S. Himmelstein\" />\n<meta name=\"citation_author_institution\" content=\"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America\" />\n<meta name=\"citation_author_institution\" content=\"Related Sciences\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-3012-7446\" />\n<meta name=\"twitter:creator\" content=\"@dhimmel\" />\n<meta name=\"citation_author\" content=\"Jeremy P. Kamil\" />\n<meta name=\"citation_author_institution\" content=\"Department of Microbiology and Immunology, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0001-8422-7656\" />\n<meta name=\"citation_author\" content=\"Jesse G. Meyer\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0003-2753-3926\" />\n<meta name=\"citation_author\" content=\"Ariel I. Mundo\" />\n<meta name=\"citation_author_institution\" content=\"Department of Biomedical Engineering, University of Arkansas, Fayetteville, Arkansas, USA\" />\n<meta name=\"citation_author_orcid\" content=\"0000-0002-6014-4538\" />\n<link rel=\"canonical\" href=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"og:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta property=\"twitter:url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_fulltext_html_url\" content=\"https://greenelab.github.io/covid19-review/\" />\n<meta name=\"citation_pdf_url\" content=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"application/pdf\" href=\"https://greenelab.github.io/covid19-review/manuscript.pdf\" />\n<link rel=\"alternate\" type=\"text/html\" href=\"https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/\" />\n<meta name=\"manubot_html_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/\" />\n<meta name=\"manubot_pdf_url_versioned\" content=\"https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta property=\"twitter:card\" content=\"summary_large_image\" />\n<meta property=\"og:image\" content=\"https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png\" />\n<meta property=\"twitter:image\" content=\"https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png\" />\n<link rel=\"icon\" type=\"image/png\" sizes=\"192x192\" href=\"https://manubot.org/favicon-192x192.png\" />\n<link rel=\"mask-icon\" href=\"https://manubot.org/safari-pinned-tab.svg\" color=\"#ad1457\" />\n<meta name=\"theme-color\" content=\"#ad1457\" />\n<!-- end Manubot generated metadata -->\n",
     "bibliography": [
       "content/manual-references-2021-02-08.json",
       "content/manual-references.bib",
@@ -77,10 +77,10 @@
     "manubot-clear-requests-cache": false
   },
   "manubot": {
-    "date": "2023-01-20",
-    "date_long": "January 20, 2023",
-    "generated": "2023-01-20T22:00:28+00:00",
-    "generated_date_long": "January 20, 2023",
+    "date": "2023-01-24",
+    "date_long": "January 24, 2023",
+    "generated": "2023-01-24T02:17:08+00:00",
+    "generated_date_long": "January 24, 2023",
     "randomize_author_order": false,
     "authors": [
       {
@@ -2728,18 +2728,18 @@
       "repo_slug": "greenelab/covid19-review",
       "repo_owner": "greenelab",
       "repo_name": "covid19-review",
-      "commit": "e1667739727de0e773dd80c8214fa4d6d6112cbd",
-      "triggering_commit": "e1667739727de0e773dd80c8214fa4d6d6112cbd",
-      "build_url": "https://github.com/greenelab/covid19-review/commit/e1667739727de0e773dd80c8214fa4d6d6112cbd/checks",
-      "job_url": "https://github.com/greenelab/covid19-review/actions/runs/3971523699"
+      "commit": "3668a38bb18729aea9d5298d870da0046319e291",
+      "triggering_commit": "3668a38bb18729aea9d5298d870da0046319e291",
+      "build_url": "https://github.com/greenelab/covid19-review/commit/3668a38bb18729aea9d5298d870da0046319e291/checks",
+      "job_url": "https://github.com/greenelab/covid19-review/actions/runs/3992348006"
     },
     "html_url": "https://greenelab.github.io/covid19-review/",
     "pdf_url": "https://greenelab.github.io/covid19-review/manuscript.pdf",
-    "html_url_versioned": "https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/",
-    "pdf_url_versioned": "https://greenelab.github.io/covid19-review/v/e1667739727de0e773dd80c8214fa4d6d6112cbd/manuscript.pdf",
+    "html_url_versioned": "https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/",
+    "pdf_url_versioned": "https://greenelab.github.io/covid19-review/v/3668a38bb18729aea9d5298d870da0046319e291/manuscript.pdf",
     "manubot_version": "0.5.5",
     "rootstock_commit": "b7a5c3f80d23ecb53de321822e2a2239209e01c7",
-    "thumbnail_url": "https://github.com/greenelab/covid19-review/raw/e1667739727de0e773dd80c8214fa4d6d6112cbd/content/images/thumbnail.png",
+    "thumbnail_url": "https://github.com/greenelab/covid19-review/raw/3668a38bb18729aea9d5298d870da0046319e291/content/images/thumbnail.png",
     "manuscript_stats": {
       "word_count": 161510
     }
@@ -2804,21 +2804,21 @@
   "cord19_total_preprints": "42343",
   "cord19_total_pubs": "1056660",
   "cord19_update_date": "2022-06-02",
-  "csse_cases": "667,918,207",
-  "csse_commit": "2b39cdd74ca616cc3552bacb51fc5b7a8f0b8689",
-  "csse_date_pretty": "January 18, 2023",
-  "csse_deaths": "6,729,898",
-  "csse_deaths_figure": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/csse/csse-deaths.png",
-  "csse_update_time_utc": "2023-01-20T00:19:40.258150",
+  "csse_cases": "668,835,703",
+  "csse_commit": "2ea8a39bf75db90d1fda4b67fc03e8727ea86780",
+  "csse_date_pretty": "January 22, 2023",
+  "csse_deaths": "6,738,594",
+  "csse_deaths_figure": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/csse/csse-deaths.png",
+  "csse_update_time_utc": "2023-01-24T00:19:11.715636",
   "ebm_all_trials": "6,987",
   "ebm_commit_date": "2021-06-23T10:30:32Z",
   "ebm_commit_date_pretty": "June 23, 2021",
   "ebm_commit_sha": "e407b36dd5215e6b412078c47509ffb2cb4ca2f7",
   "ebm_date_pretty": "December 31, 2020",
   "ebm_interv_trials": "3,962",
-  "ebm_map_figure": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-map.png",
+  "ebm_map_figure": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-map.png",
   "ebm_tocilizumab_ct": "73",
-  "ebm_trials_figure": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/ebmdatalab/ebmdatalab-trials.png",
+  "ebm_trials_figure": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/ebmdatalab/ebmdatalab-trials.png",
   "ebm_trials_results": "98",
   "ebm_trials_results_citekeys": [
     "doi:10.1001/jama.2020.10044",
@@ -2921,38 +2921,38 @@
     "url:https://clinicaltrials.gov/ct2/show/results/NCT04542694",
     "url:https://jrct.niph.go.jp/en-latest-detail/jRCTs041190120"
   ],
-  "ebm_update_time_utc": "2023-01-20T00:19:49.603124",
+  "ebm_update_time_utc": "2023-01-24T00:19:22.511683",
   "Covaxin_continents": "Africa, Asia, Europe, and South America",
   "Covaxin_country_count": "31",
   "Sinovac_continents": "Africa, Asia, Europe, North America, and South America",
   "Sinovac_country_count": "66",
   "owid_RNA_count": "2",
   "owid_RNA_countries": "169",
-  "owid_RNA_map": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/RNA.png",
+  "owid_RNA_map": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/RNA.png",
   "owid_VLP_count": "1",
   "owid_VLP_countries": "1",
-  "owid_VLP_map": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/VLP.png",
-  "owid_commit_date": "2023-01-19T11:26:07Z",
-  "owid_commit_date_pretty": "January 19, 2023",
-  "owid_commit_sha": "77b11a9c1f9f73f4fb738e5c54786c9938deefde",
-  "owid_doses_bargraph": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/OWID_dosesByContinent.png",
-  "owid_doses_scatterplot": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/OWID_doseTypebyGDP.png",
+  "owid_VLP_map": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/VLP.png",
+  "owid_commit_date": "2023-01-23T10:48:53Z",
+  "owid_commit_date_pretty": "January 23, 2023",
+  "owid_commit_sha": "d2b56e1523f56f74051d5efe5c4f472acd6c9eba",
+  "owid_doses_bargraph": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/OWID_dosesByContinent.png",
+  "owid_doses_scatterplot": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/OWID_doseTypebyGDP.png",
   "owid_inactivated_count": "10",
   "owid_inactivated_countries": "118",
-  "owid_inactivated_map": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/inactivated.png",
-  "owid_most_recent_date": "January 18, 2023",
+  "owid_inactivated_map": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/inactivated.png",
+  "owid_most_recent_date": "January 22, 2023",
   "owid_non_replicating_viral_vector_count": "5",
   "owid_non_replicating_viral_vector_countries": "202",
-  "owid_non_replicating_viral_vector_map": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/non_replicating_viral_vector.png",
+  "owid_non_replicating_viral_vector_map": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/non_replicating_viral_vector.png",
   "owid_plasmid_vectored_count": "0",
   "owid_plasmid_vectored_countries": "0",
   "owid_protein_subunit_count": "9",
   "owid_protein_subunit_countries": "42",
-  "owid_protein_subunit_map": "https://github.com/greenelab/covid19-review/raw/5b035ad950bef68f678c4ff9b94a80719787c328/owiddata/maps/protein_subunit.png",
+  "owid_protein_subunit_map": "https://github.com/greenelab/covid19-review/raw/7839d26d55be09a76ddd7a1193790bfbf112b07d/owiddata/maps/protein_subunit.png",
   "owid_total_countries": "223",
   "owid_vaccine_counts": "28",
-  "owid_worldwide_daily_rate": "260.0 per million",
-  "owid_worldwide_date": "January 12, 2023",
+  "owid_worldwide_daily_rate": "251.0 per million",
+  "owid_worldwide_date": "January 16, 2023",
   "owid_worldwide_total_vaccinations": "13.0 billion",
   "viper_approved_DNA": "| Vaccine                                      | Company                     | Platform                     |\n|:---------------------------------------------|:----------------------------|:-----------------------------|\n| iNCOVACC                                     | Bharat Biotech              | non replicating viral vector |\n| Convidecia                                   | CanSino                     | non replicating viral vector |\n| Convidecia Air                               | CanSino                     | non replicating viral vector |\n| Gam-COVID-Vac                                | Gamaleya                    | non replicating viral vector |\n| Sputnik Light                                | Gamaleya                    | non replicating viral vector |\n| Sputnik V                                    | Gamaleya                    | non replicating viral vector |\n| Jcovden                                      | Janssen (Johnson & Johnson) | non replicating viral vector |\n| Vaxzevria                                    | Oxford/AstraZeneca          | non replicating viral vector |\n| Covishield (Oxford/ AstraZeneca formulation) | Serum Institute of India    | non replicating viral vector |\n| ZyCoV-D                                      | Zydus Cadila                | plasmid vectored             |",
   "viper_approved_RNA": "| Vaccine                                       | Company                            |\n|:----------------------------------------------|:-----------------------------------|\n| GEMCOVAC-19                                   | Gennova Biopharmaceuticals Limited |\n| Spikevax                                      | Moderna                            |\n| Spikevax Bivalent Original/Omicron BA.1       | Moderna                            |\n| Spikevax Bivalent Original/Omicron BA.4/BA.5  | Moderna                            |\n| Comirnaty                                     | Pfizer/BioNTech                    |\n| Comirnaty Bivalent Original/Omicron BA.1      | Pfizer/BioNTech                    |\n| Comirnaty Bivalent Original/Omicron BA.4/BA.5 | Pfizer/BioNTech                    |\n| TAK-919 (Moderna formulation)                 | Takeda                             |\n| AWcorna                                       | Walvax                             |",